PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
15374562-1	2004	A 36-year-old, 204-kg parturient with a past medical history of Factor V Leiden requiring enoxaparin therapy developed a postdural puncture headache.	Enoxaparin	90-100	coagulation factor V	Homo sapiens	64-79
15249498-3	2004	The recommended dose of enoxaparin of 1 mg/kg BID was used throughout the population except when physicians decided on dose reduction because of a history of a recent bleeding event or because of a high bleeding risk.	Enoxaparin	24-34	BH3 interacting domain death agonist	Homo sapiens	46-49
15210403-13	2004	In most instances LMWH (dalteparin, enoxaparin, nadroparin) treatment for DVT may be given once daily at a fixed dose without any harm, based on a prolonged antithrombin activity.	Enoxaparin	36-46	serpin family C member 1	Homo sapiens	157-169
15238596-0	2004	Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.	Enoxaparin	65-75	serpin family C member 1	Homo sapiens	106-118
15091002-14	2004	The more profound inhibition of thrombin generation induced by enoxaparin is due to its supplementary anti-activated factor II activity.	Enoxaparin	63-73	coagulation factor II, thrombin	Homo sapiens	32-40
14633147-8	2003	Both HGF and activin A were markedly increased at each interval of enoxaparin-anticoagulated hemodialysis, and follistatin was increased at 10 minutes (all P < 0.0001).	Enoxaparin	67-77	hepatocyte growth factor	Homo sapiens	5-8
14576044-8	2004	These peptides (1 mg/300 g rat) neutralized 1 U/mL anti-Factor Xa activity of enoxaparin in rats within 1 to 2 minutes.	Enoxaparin	78-88	coagulation factor X	Homo sapiens	56-65
15091002-8	2004	Concentrations of enoxaparin achieved in prophylaxis (0.1-0.25 anti-FXa IU/ml) did not significantly modify these parameters.	Enoxaparin	18-28	coagulation factor X	Homo sapiens	68-71
15091002-11	2004	In the presence of enoxaparin concentrations equal to or higher than 0.8 anti-FXa IU/ml, the inhibition of thrombin generation was higher than 80%.	Enoxaparin	19-29	coagulation factor X	Homo sapiens	78-81
15091002-11	2004	In the presence of enoxaparin concentrations equal to or higher than 0.8 anti-FXa IU/ml, the inhibition of thrombin generation was higher than 80%.	Enoxaparin	19-29	coagulation factor II, thrombin	Homo sapiens	107-115
14633147-9	2003	The early increments in HGF and follistatin directly depended on the dose of enoxaparin (both P < 0.030).	Enoxaparin	77-87	hepatocyte growth factor	Homo sapiens	24-27
12968985-6	2003	A creatinine clearance of 30 ml min(-1) was associated with a decrease in enoxaparin clearance of 27% compared with that in a patient with a median creatinine clearance of 88 ml min-1, and was related to a 1.5- and 3.8-fold increase in the risk of "all" and "major" haemorrhagic episodes, respectively.	Enoxaparin	74-84	CD59 molecule (CD59 blood group)	Homo sapiens	32-38
12968985-6	2003	A creatinine clearance of 30 ml min(-1) was associated with a decrease in enoxaparin clearance of 27% compared with that in a patient with a median creatinine clearance of 88 ml min-1, and was related to a 1.5- and 3.8-fold increase in the risk of "all" and "major" haemorrhagic episodes, respectively.	Enoxaparin	74-84	CD59 molecule (CD59 blood group)	Homo sapiens	178-183
12937038-8	2003	Preterm infants required higher doses of enoxaparin than full term infants to maintain anti-(factor Xa) levels in the target range (2.1 v 1.7 mg/kg/12 h).	Enoxaparin	41-51	coagulation factor X	Homo sapiens	93-102
14522366-5	2003	Statistical data revealed that treatment with enoxaparin resulted in a significant decrease in monocyte adhesion, expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin, translocation of NF-kappaB, as well as in the level of intracellular reactive oxygen species.	Enoxaparin	46-56	intercellular adhesion molecule 1	Homo sapiens	128-161
14522366-5	2003	Statistical data revealed that treatment with enoxaparin resulted in a significant decrease in monocyte adhesion, expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin, translocation of NF-kappaB, as well as in the level of intracellular reactive oxygen species.	Enoxaparin	46-56	intercellular adhesion molecule 1	Homo sapiens	163-169
14522366-5	2003	Statistical data revealed that treatment with enoxaparin resulted in a significant decrease in monocyte adhesion, expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin, translocation of NF-kappaB, as well as in the level of intracellular reactive oxygen species.	Enoxaparin	46-56	vascular cell adhesion molecule 1	Homo sapiens	172-205
14522366-5	2003	Statistical data revealed that treatment with enoxaparin resulted in a significant decrease in monocyte adhesion, expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin, translocation of NF-kappaB, as well as in the level of intracellular reactive oxygen species.	Enoxaparin	46-56	vascular cell adhesion molecule 1	Homo sapiens	207-213
14522366-5	2003	Statistical data revealed that treatment with enoxaparin resulted in a significant decrease in monocyte adhesion, expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin, translocation of NF-kappaB, as well as in the level of intracellular reactive oxygen species.	Enoxaparin	46-56	selectin E	Homo sapiens	219-229
14522366-5	2003	Statistical data revealed that treatment with enoxaparin resulted in a significant decrease in monocyte adhesion, expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin, translocation of NF-kappaB, as well as in the level of intracellular reactive oxygen species.	Enoxaparin	46-56	nuclear factor kappa B subunit 1	Homo sapiens	248-257
14522366-6	2003	These results suggest that enoxaparin reduces the high glucose-induced activation of endothelial cells by inhibiting monocyte adhesion through a mechanism that involves cell adhesion molecules and NF-kappaB.	Enoxaparin	27-37	nuclear factor kappa B subunit 1	Homo sapiens	197-206
12937038-9	2003	Infants with congenital heart disease (CHD) required less enoxaparin than those without CHD to maintain an anti-(factor Xa) level in the target range (1.7 v 2.1 mg/kg/12 h).	Enoxaparin	58-68	coagulation factor X	Homo sapiens	113-122
12897120-0	2003	Striking increase in circulating hepatocyte growth factor during enoxaparin-anticoagulated haemodialysis.	Enoxaparin	65-75	hepatocyte growth factor	Homo sapiens	33-57
12808176-6	2003	TF and PF 1+2 did not change, while TFPI levels, compared with baseline, increased at each interval in enoxaparin-anticoagulated HD patients (all P<0.0001).	Enoxaparin	103-113	tissue factor pathway inhibitor	Homo sapiens	36-40
12784820-0	2003	Primary PCI for ST-segment elevation myocardial infarction in a patient treated with subcutaneous enoxaparin utilizing point-of-care Enox test.	Enoxaparin	98-108	JPX transcript, XIST activator	Homo sapiens	133-137
12801846-8	2003	With long periods of incubation (24-48h), both unfractionated heparin and enoxaparin significantly increased TFPI release (control vs. unfractionated heparin, p<0.05-0.001; control vs. enoxaparin, p<0.01-0.001) and also reduced the release of vWF in the culture medium, though no variations in endothelial cell procoagulant activity or TF content were observed.	Enoxaparin	74-84	tissue factor pathway inhibitor	Homo sapiens	109-113
12801846-8	2003	With long periods of incubation (24-48h), both unfractionated heparin and enoxaparin significantly increased TFPI release (control vs. unfractionated heparin, p<0.05-0.001; control vs. enoxaparin, p<0.01-0.001) and also reduced the release of vWF in the culture medium, though no variations in endothelial cell procoagulant activity or TF content were observed.	Enoxaparin	74-84	von Willebrand factor	Homo sapiens	249-252
12801846-8	2003	With long periods of incubation (24-48h), both unfractionated heparin and enoxaparin significantly increased TFPI release (control vs. unfractionated heparin, p<0.05-0.001; control vs. enoxaparin, p<0.01-0.001) and also reduced the release of vWF in the culture medium, though no variations in endothelial cell procoagulant activity or TF content were observed.	Enoxaparin	74-84	coagulation factor III, tissue factor	Homo sapiens	109-111
12784820-1	2003	The superiority of enoxaparin compared with unfractionated heparin in the medical management of patients with non-ST elevation acute coronary syndromes (NSTE ACS) has been demonstrated in clinical trials.	Enoxaparin	19-29	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	158-161
12784820-3	2003	Whether enoxaparin is superior to unfractionated heparin in patients with NSTE ACS under-going early invasive strategy is currently being tested in a large clinical trial.	Enoxaparin	8-18	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	79-82
15041274-2	2003	A new point-of-care device, Rapidpoint ENOX, was recently developed to measure clotting times with enoxaparin use.	Enoxaparin	99-109	JPX transcript, XIST activator	Homo sapiens	39-43
12730628-2	2003	NICE-4, a recent PCI observational study, evaluated a reduced dose of intravenous (IV) enoxaparin (0.75 mg/kg) with abciximab.	Enoxaparin	87-97	ubiquitin associated protein 2 like	Homo sapiens	0-6
12730628-9	2003	Our small observational study shows that IV enoxaparin is safe and efficacious during PCI when given at a dose 33% lower than previously reported in conjunction with any GP IIb/IIIa inhibitor and Angio-Seal.	Enoxaparin	44-54	integrin subunit alpha 2b	Homo sapiens	170-176
12730628-10	2003	However, large, randomized PCI trials are needed to confirm the clinical efficacy, safety and cost-effectiveness of lower doses of enoxaparin with GPIIb/IIIa inhibitors and vascular closure devices.	Enoxaparin	131-141	integrin subunit alpha 2b	Homo sapiens	147-152
12891293-14	2003	The use of clopidogrel in similar patients treated with aspirin and enoxaparin was associated with elevated levels of TPA and D-dimer what presumably reflected augmentation of fibrinolytic activity.	Enoxaparin	68-78	plasminogen activator, tissue type	Homo sapiens	118-121
15041274-3	2003	OBJECTIVES: To correlate ENOX times with anti-Xa levels among patients receiving enoxaparin.	Enoxaparin	81-91	JPX transcript, XIST activator	Homo sapiens	25-29
12459075-14	2002	CONCLUSIONS: Combined enoxaparin-abciximab as an adjuvant therapy during PTCA was safe and associated with a low incidence of major bleeding, major ischemic in-hospital events, and post-procedural CPK elevation.	Enoxaparin	22-32	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha	Homo sapiens	197-200
11901299-4	2002	Adhesion assays, ELISA, and flow cytometric analysis revealed that pretreatment with enoxaparin, at a relevant plasma concentration (16 microg/ml), acts upon activation of VEC by inhibition of lipopolysaccharide-induced E-selectin expression and tumor necrosis factor stimulated ICAM-1 expression, thus reducing monocyte adhesion to VEC.	Enoxaparin	85-95	selectin E	Homo sapiens	220-230
12355033-7	2002	Platelet reactivity was greater in blood treated with UFH than in blood exposed to enoxaparin with respect to P-selectin expression (by 7 +/- 1.1%, p, < 0.0001) in response to 1 microM ADP.	Enoxaparin	83-93	selectin P	Homo sapiens	110-120
12382130-0	2002	Medroxyprogesterone acetate, enoxaparin and pentoxyfylline cause alterations in lipid peroxidation, paraoxonase (PON1) activities and homocysteine levels in the acute oxidative stress in an experimental model of spinal cord injury.	Enoxaparin	29-39	paraoxonase 1	Rattus norvegicus	113-117
12040334-0	2002	Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.	Enoxaparin	124-134	coagulation factor X	Homo sapiens	59-68
12040334-3	2002	PURPOSE: The purpose of our study was the determination of the impact of patient age, sex, body weight, and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in patients with ACS.	Enoxaparin	191-201	coagulation factor X	Homo sapiens	126-135
11901299-4	2002	Adhesion assays, ELISA, and flow cytometric analysis revealed that pretreatment with enoxaparin, at a relevant plasma concentration (16 microg/ml), acts upon activation of VEC by inhibition of lipopolysaccharide-induced E-selectin expression and tumor necrosis factor stimulated ICAM-1 expression, thus reducing monocyte adhesion to VEC.	Enoxaparin	85-95	tumor necrosis factor	Homo sapiens	246-267
11901299-4	2002	Adhesion assays, ELISA, and flow cytometric analysis revealed that pretreatment with enoxaparin, at a relevant plasma concentration (16 microg/ml), acts upon activation of VEC by inhibition of lipopolysaccharide-induced E-selectin expression and tumor necrosis factor stimulated ICAM-1 expression, thus reducing monocyte adhesion to VEC.	Enoxaparin	85-95	intercellular adhesion molecule 1	Homo sapiens	279-285
11812067-12	2002	These findings regarding enoxaparin add to the data to be considered by clinicians when selecting an antithrombin for the acute phase of management of unstable angina/non-ST elevation myocardial infarction.	Enoxaparin	25-35	serpin family C member 1	Homo sapiens	101-113
12001541-7	2002	The ACE study (Anticoagulation in Cardioversion using Enoxaparin) is a randomized, prospective, open-label multicenter trial comparing the safety and efficacy of subcutaneous enoxaparin with intravenous heparin/oral phenprocoumon before and after cardioversion (stratified to TEE guidance or no TEE guidance).	Enoxaparin	54-64	angiotensin I converting enzyme	Homo sapiens	4-7
12001541-7	2002	The ACE study (Anticoagulation in Cardioversion using Enoxaparin) is a randomized, prospective, open-label multicenter trial comparing the safety and efficacy of subcutaneous enoxaparin with intravenous heparin/oral phenprocoumon before and after cardioversion (stratified to TEE guidance or no TEE guidance).	Enoxaparin	175-185	angiotensin I converting enzyme	Homo sapiens	4-7
11748259-6	2001	Both heparin and the low-molecular weight heparin enoxaparin significantly inhibited MPO binding and protein nitrotyrosine (NO(2)Tyr) formation in both cultured endothelial cells and rat aortic tissues.	Enoxaparin	50-60	myeloperoxidase	Rattus norvegicus	85-88
11755953-3	2001	We have estimated the concentration of circulating thrombin-antithrombin (TAT) complex in patients subjected to transperitoneal nephrectomy and randomized into controls and who received 40-mg enoxaparin 12 h before and 12 h after the operation and then once daily for 7 days.	Enoxaparin	192-202	coagulation factor II, thrombin	Homo sapiens	51-59
11755953-3	2001	We have estimated the concentration of circulating thrombin-antithrombin (TAT) complex in patients subjected to transperitoneal nephrectomy and randomized into controls and who received 40-mg enoxaparin 12 h before and 12 h after the operation and then once daily for 7 days.	Enoxaparin	192-202	serpin family C member 1	Homo sapiens	60-72
11668418-3	2001	Unfractionated heparin (UFH) as well as low molecular weight heparin (LMWH) (enoxaparin) inhibited the mitogenic effects of FXa, thrombin and fetal calf serum (FCS), but did not reduce mitogenesis induced by PDGF.	Enoxaparin	77-87	coagulation factor X	Homo sapiens	124-127
11564011-10	2001	RESULTS: Enoxaparin and heparin significantly ameliorated the severity of dinitrobenzene sulphonic acid- and iodoacetamide-induced colitis as demonstrated by a decrease in mucosal lesion area, colonic weight and mucosal myeloperoxidase and nitric oxide synthase activities.	Enoxaparin	9-19	myeloperoxidase	Rattus norvegicus	220-235
11686357-0	2001	Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.	Enoxaparin	14-24	coagulation factor II, thrombin	Homo sapiens	55-63
11505079-0	2001	Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia.	Enoxaparin	26-36	asparaginase and isoaspartyl peptidase 1	Homo sapiens	44-58
11505079-2	2001	Enoxaparin was given every 24 h subcutaneously at a median dose of 0.84 mg/kg per day (range, 0.45-1.33 mg/kg per day) starting at the first dose of L-asparaginase until 1 week after the last dose.	Enoxaparin	0-10	asparaginase and isoaspartyl peptidase 1	Homo sapiens	149-163
11505079-8	2001	Enoxaparin is safe and seems to be effective in prevention of thromboembolism in ALL patients during L-asparaginase therapy.	Enoxaparin	0-10	asparaginase and isoaspartyl peptidase 1	Homo sapiens	101-115
11427638-5	2001	On bivariate regression analysis, vWF : Ag level was directly associated with the presence of CVD, age, fibrinogen and the use of enoxaparin (vs unfractionated heparin) during HD procedures, and inversely with albumin and pre-dialysis BP.	Enoxaparin	130-140	von Willebrand factor	Homo sapiens	34-37
11460016-8	2001	Interestingly, subjects with the intron 7 CC genotype had significantly higher total TFPI levels than those with the TT genotype before and after an enoxaparin injection.	Enoxaparin	149-159	tissue factor pathway inhibitor	Homo sapiens	85-89
11454528-2	2001	Since enoxaparin appears to offer clinical advantages over UFH in managing ACS, markers of thrombin generation, endothelial function and acute phase response could manifest different responses to UFH or enoxaparin.	Enoxaparin	203-213	coagulation factor II, thrombin	Homo sapiens	91-99
11454528-7	2001	In comparison with the baseline levels of the UFH- and enoxaparin-treated patients, Fg showed a significant increase at 48 h and TFPI at 6, 12 and 24 hours.	Enoxaparin	55-65	tissue factor pathway inhibitor	Homo sapiens	129-133
11454528-10	2001	INTERPRETATION AND CONCLUSIONS: Markers of thrombin generation, endothelial function and acute-phase reactants manifest a similar response to UFH and enoxaparin.	Enoxaparin	150-160	coagulation factor II, thrombin	Homo sapiens	43-51
11454528-11	2001	An increase in thrombin generation may be a result of persistently activated inflammatory and endothelial processes, despite UFH and enoxaparin treatment.	Enoxaparin	133-143	coagulation factor II, thrombin	Homo sapiens	15-23
11668418-3	2001	Unfractionated heparin (UFH) as well as low molecular weight heparin (LMWH) (enoxaparin) inhibited the mitogenic effects of FXa, thrombin and fetal calf serum (FCS), but did not reduce mitogenesis induced by PDGF.	Enoxaparin	77-87	coagulation factor II, thrombin	Homo sapiens	129-137
11369420-2	2001	Therefore, enoxaparin might have a similar advantage over heparin when used with a GPIIb/IIIa antagonist (RPR109891) in coronary thrombolysis.	Enoxaparin	11-21	integrin subunit alpha 2b	Canis lupus familiaris	83-88
11287128-2	2001	Titration of antithrombin with both low molecular weight heparin (LMWH) (enoxaparin, fragmin and ardeparin) and unfractionated heparin (UFH) produced an equivalent fluorescence increase and indicates similar affinity of all heparin preparations to antithrombin.	Enoxaparin	73-83	serpin family C member 1	Homo sapiens	13-25
11323025-5	2001	At 0.01 U/ml, enoxaparin exhibited a stronger inhibition of TF-induced platelet activation compared to ardeparin and dalteparin.	Enoxaparin	14-24	coagulation factor III, tissue factor	Homo sapiens	60-62
11323025-7	2001	Since enoxaparin produced the best concentration-dependent inhibition of P-selectin expression (saline: 76 +/- 10% vs. 1.0 U/ml enoxaparin: 18 +/- 7%; P < .02) and platelet aggregate formation (saline: 63 +/- 7% vs. 1.0 U/ml enoxaparin: 35 +/- 6%, P < .035), this agent was used for additional studies.	Enoxaparin	6-16	selectin P	Homo sapiens	73-83
11323025-12	2001	Thus, at therapeutic concentrations (0.8-1.2 U/ml), enoxaparin itself was capable of inhibiting TF-mediated activation of platelets to > 70%; whereas tirofiban failed to produce such concentration-dependent inhibition.	Enoxaparin	52-62	coagulation factor III, tissue factor	Homo sapiens	96-98
11286313-6	2001	Similar results were demonstrated in the National Investigators Collaborating on Enoxaparin (NICE-4) study using a combination of abciximab and enoxaparin in patients undergoing PCI.	Enoxaparin	81-91	ubiquitin associated protein 2 like	Homo sapiens	93-99
11286313-6	2001	Similar results were demonstrated in the National Investigators Collaborating on Enoxaparin (NICE-4) study using a combination of abciximab and enoxaparin in patients undergoing PCI.	Enoxaparin	144-154	ubiquitin associated protein 2 like	Homo sapiens	93-99
14728009-1	2001	Enoxaparin (enoxaparin sodium) is a low-molecular-weight heparin that binds to and increases the activity of antithrombin III.	Enoxaparin	0-10	serpin family C member 1	Homo sapiens	109-125
11482207-0	2001	[The influence of clexane on the fibronectin content in the blood plasma in patients with destructive pancreatitis].	Enoxaparin	18-25	fibronectin 1	Homo sapiens	33-44
11482207-3	2001	Application of clexane had promoted the fibronectin level raising in the blood serum in patients with sterile and infected pancreatic necrosis.	Enoxaparin	15-22	fibronectin 1	Homo sapiens	40-51
14728009-1	2001	Enoxaparin (enoxaparin sodium) is a low-molecular-weight heparin that binds to and increases the activity of antithrombin III.	Enoxaparin	12-29	serpin family C member 1	Homo sapiens	109-125
11030526-0	2000	Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery.	Enoxaparin	91-101	tissue factor pathway inhibitor	Homo sapiens	7-38
11092649-7	2000	Enoxaparin had a greater benefit among patients with elevated vs. normal cTnI (p = 0.03), achieving a 47% reduction in the risk of death, MI or urgent revascularization by 14 days in cTnI-positive patients (p = 0.007).	Enoxaparin	0-10	troponin I3, cardiac type	Homo sapiens	73-77
11092649-7	2000	Enoxaparin had a greater benefit among patients with elevated vs. normal cTnI (p = 0.03), achieving a 47% reduction in the risk of death, MI or urgent revascularization by 14 days in cTnI-positive patients (p = 0.007).	Enoxaparin	0-10	troponin I3, cardiac type	Homo sapiens	183-187
11092649-9	2000	Treatment with enoxaparin reduces the risk associated with elevated cTnI.	Enoxaparin	15-25	troponin I3, cardiac type	Homo sapiens	68-72
11062276-3	2000	METHODS: A LMWH, enoxaparin 1 mg/kg BID, was used as bridging anticoagulation therapy in 24 consecutive patients admitted to a university stroke center in whom the treatment plan included transition from acute to chronic anticoagulation.	Enoxaparin	17-27	BH3 interacting domain death agonist	Homo sapiens	36-39
11190908-0	2001	Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery.	Enoxaparin	91-101	tissue factor pathway inhibitor	Homo sapiens	7-38
11096663-2	2000	Similarly, the low molecular weight heparin (LMWH), enoxaparin, has demonstrated superior efficacy when compared with unfractionated heparin (UFH) in the treatment of patients with non-ST elevation ACS.	Enoxaparin	52-62	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	198-201
10947916-8	2000	Thrombin generation was decreased by an additional 2 to 3% (absolute reduction) with high concentrations of enoxaparin in combination with either eptifibatide or abciximab.	Enoxaparin	108-118	coagulation factor II, thrombin	Homo sapiens	0-8
11019977-7	2000	At high pharmacologic concentrations, unfractionated heparin and enoxaparin, but not hirudin, further reduced factor V/Va binding to the surface of activated platelets in the presence of GPIIb-IIa antagonists.	Enoxaparin	65-75	integrin subunit alpha 2b	Homo sapiens	187-192
10847421-3	2000	In the present study, the dose-response relationship for escalating doses of two LMWHs, dalteparin and enoxaparin, on the release of endogenous TFPI was investigated.	Enoxaparin	103-113	tissue factor pathway inhibitor	Homo sapiens	144-148
10728020-0	2000	Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.	Enoxaparin	0-10	coagulation factor X	Homo sapiens	72-86
10728020-0	2000	Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.	Enoxaparin	0-10	coagulation factor X	Homo sapiens	112-121
10728020-11	2000	CONCLUSION: We conclude that enoxaparin in plasma concentrations achieved routinely in clinical practice is able to: (1) inhibit tissue factor mediated extrinsic coagulation by preventing platelet surface prothrombinase assembly, and (2) inactivate platelet prothrombinase activity and resulting thrombin generation.	Enoxaparin	29-39	coagulation factor X	Homo sapiens	205-219
10728020-11	2000	CONCLUSION: We conclude that enoxaparin in plasma concentrations achieved routinely in clinical practice is able to: (1) inhibit tissue factor mediated extrinsic coagulation by preventing platelet surface prothrombinase assembly, and (2) inactivate platelet prothrombinase activity and resulting thrombin generation.	Enoxaparin	29-39	coagulation factor X	Homo sapiens	258-272
10728020-11	2000	CONCLUSION: We conclude that enoxaparin in plasma concentrations achieved routinely in clinical practice is able to: (1) inhibit tissue factor mediated extrinsic coagulation by preventing platelet surface prothrombinase assembly, and (2) inactivate platelet prothrombinase activity and resulting thrombin generation.	Enoxaparin	29-39	coagulation factor II, thrombin	Homo sapiens	208-216
11096663-3	2000	Algorithms for seamless integration of pharmacotherpy through the course of hospitalization for patients who present with ACS and who require PCI will likely combine therapy with enoxaparin and platelet GP IIb/IIIa blockade (abciximab).	Enoxaparin	179-189	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	122-125
10731289-4	2000	The preliminary experience with combining abciximab and intravenous enoxaparin during percutaneous coronary intervention in the NICE-4 Trial demonstrates a low incidence of minor/major bleeding (TIMI definition) and transfusion and infrequent major cardiac events to 30 days follow-up.	Enoxaparin	68-78	ubiquitin associated protein 2 like	Homo sapiens	128-134
10500313-12	1999	CONCLUSIONS: In this subset of patients enrolled in the ESSENCE study, enoxaparin 1 mg/kg ql2hr significantly increased anti-Xa activity above that seen with unfractionated heparin, and reduced thrombin production without prolonging the thrombin time.	Enoxaparin	71-81	coagulation factor II, thrombin	Homo sapiens	194-202
10691099-2	2000	We investigate the inhibition of clot-associated factor Xa and thrombin activities by purified human antithrombin either alone or as combination with a low molecular weight heparin (enoxaparin) as compared with unfractionated heparin (UFH).	Enoxaparin	182-192	coagulation factor II, thrombin	Homo sapiens	63-71
10606110-5	1999	Enoxaparin showed antithrombotic properties comparable to that of unfractionated heparin as measured by anti-Xa levels, with less inhibition of thrombin (factor IIa) at the time points measured (p <0.0001).	Enoxaparin	0-10	coagulation factor II, thrombin	Homo sapiens	144-152
10598348-1	1999	OBJECTIVE: The utilization, during pregnancy, of low molecular weight heparin (enoxaparine) for obstetric thromboprophylaxis for patients with activated protein C resistance, following Factor V Leiden mutation.	Enoxaparin	79-90	coagulation factor V	Homo sapiens	185-200
10500313-12	1999	CONCLUSIONS: In this subset of patients enrolled in the ESSENCE study, enoxaparin 1 mg/kg ql2hr significantly increased anti-Xa activity above that seen with unfractionated heparin, and reduced thrombin production without prolonging the thrombin time.	Enoxaparin	71-81	coagulation factor II, thrombin	Homo sapiens	237-245
10203088-0	1999	Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor-alpha production in human monocytes.	Enoxaparin	12-22	tumor necrosis factor	Homo sapiens	49-76
10203088-10	1999	RESULTS: Heparin (10 to 1000 microg/ml) and enoxaparin (1000 microg/ml) significantly enhanced LPS-induced TNF-alpha release.	Enoxaparin	44-54	tumor necrosis factor	Homo sapiens	107-116
10203088-12	1999	Blockade of CD14 abrogated both LPS-induced TNF-alpha release and the effect of heparin or enoxaparin to enhance LPS-induced TNF-alpha release.	Enoxaparin	91-101	CD14 molecule	Homo sapiens	12-16
10203088-12	1999	Blockade of CD14 abrogated both LPS-induced TNF-alpha release and the effect of heparin or enoxaparin to enhance LPS-induced TNF-alpha release.	Enoxaparin	91-101	tumor necrosis factor	Homo sapiens	125-134
9674734-2	1998	In the present study we investigated whether subcutaneous (s.c.) administration of a low molecular weight heparin (LMWH), enoxaparin, had a different effect on intravascular pools of TFPI compared with continuous i.v.	Enoxaparin	122-132	tissue factor pathway inhibitor	Homo sapiens	183-187
9711933-0	1998	Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin.	Enoxaparin	124-134	von Willebrand factor	Homo sapiens	18-39
9711933-9	1998	Moreover the early increase of von Willebrand factor was more frequent and more severe with unfractionated heparin than with enoxaparin (mean change was +8.7+/-8.8% with enoxaparin versus +93.9+/-11.7% with unfractionated heparin, P<0.0001).	Enoxaparin	125-135	von Willebrand factor	Homo sapiens	31-52
9711933-9	1998	Moreover the early increase of von Willebrand factor was more frequent and more severe with unfractionated heparin than with enoxaparin (mean change was +8.7+/-8.8% with enoxaparin versus +93.9+/-11.7% with unfractionated heparin, P<0.0001).	Enoxaparin	170-180	von Willebrand factor	Homo sapiens	31-52
9711933-13	1998	Enoxaparin provides protection as evidenced by the reduced release of von Willebrand factor, which represents a favorable prognostic finding.	Enoxaparin	0-10	von Willebrand factor	Homo sapiens	70-91
8703665-15	1995	The calculated surface under the thrombin generation curve vs time (or thrombin potential) at peak was significantly higher after reviparin than after enoxaparin (367 +/- 53 UA vs 305 +/- 48 UA respectively, P < 0.05).	Enoxaparin	151-161	coagulation factor II, thrombin	Homo sapiens	33-41
10163420-9	1996	Enoxaparin, a LMWH with a mean molecular weight of 4 to 5kD, is reported to have approximately 5 times less activity against thrombin than UFH, for equivalent anti-factor Xa activity.	Enoxaparin	0-10	coagulation factor II, thrombin	Homo sapiens	125-133
8703665-7	1995	The overall 24 h profiles of the plasma anti-Xa and anti-thrombin activities were similar for reviparin and enoxaparin.	Enoxaparin	108-118	coagulation factor II, thrombin	Homo sapiens	57-65
9268188-5	1997	beta-TG was decreased following certoparin and enoxaparin, but not following dalteparin.	Enoxaparin	47-57	pro-platelet basic protein	Homo sapiens	0-7
8585002-8	1995	From the linear correlation between these two parameters it was found that 5 out of the 6 tested aprotinin analogues, rTAP and r-hirudin completely inhibited thrombus formation at a therapeutical (2- to 3-fold) aPTT prolongation while 4C2, heparin and enoxaparin only inhibited thrombus formation for 40 to 50 percent at a 2-fold aPTT prolongation.	Enoxaparin	252-262	pancreatic trypsin inhibitor	Bos taurus	97-106
8703665-15	1995	The calculated surface under the thrombin generation curve vs time (or thrombin potential) at peak was significantly higher after reviparin than after enoxaparin (367 +/- 53 UA vs 305 +/- 48 UA respectively, P < 0.05).	Enoxaparin	151-161	coagulation factor II, thrombin	Homo sapiens	71-79
7605876-0	1995	Effect of repeated Aprosulate and Enoxaparin administration on tissue factor pathway inhibitor antigen levels.	Enoxaparin	34-44	tissue factor pathway inhibitor	Homo sapiens	63-94
8165617-6	1993	Clexane (M(r) = 4,500) also bound antithrombin III, but both histidine-rich glycoprotein and vitronectin were quantitatively significant neutralising proteins.	Enoxaparin	0-7	serpin family C member 1	Homo sapiens	34-50
7534945-8	1994	However, vWF was significantly reduced in the dextran and the dextran/enoxaparin group (p = 0.046 and 0.01 respectively) but no difference was found between the two groups.	Enoxaparin	70-80	von Willebrand factor	Homo sapiens	9-12
7900078-5	1994	Significantly higher inhibition of the thrombin potential was seen after administration of both doses of enoxaparin.	Enoxaparin	105-115	coagulation factor II, thrombin	Homo sapiens	39-47
7900078-9	1994	Excess amounts of platelet factor 4 (PF4) were able to neutralize completely the anti-thrombin activity in normal plasma spiked with enoxaparin as well as in plasma samples obtained after SC enoxaparin injection.	Enoxaparin	133-143	platelet factor 4	Homo sapiens	37-40
7900078-9	1994	Excess amounts of platelet factor 4 (PF4) were able to neutralize completely the anti-thrombin activity in normal plasma spiked with enoxaparin as well as in plasma samples obtained after SC enoxaparin injection.	Enoxaparin	133-143	coagulation factor II, thrombin	Homo sapiens	86-94
7900078-9	1994	Excess amounts of platelet factor 4 (PF4) were able to neutralize completely the anti-thrombin activity in normal plasma spiked with enoxaparin as well as in plasma samples obtained after SC enoxaparin injection.	Enoxaparin	191-201	platelet factor 4	Homo sapiens	37-40
1329919-10	1992	As Enoxaparin moderated the generation of endogenous thrombin-antithrombin III after elective knee surgery, inhibition of prothrombin activation in vivo by Enoxaparin may be important for its prophylactic antithrombotic effect.	Enoxaparin	3-13	coagulation factor II, thrombin	Homo sapiens	53-61
8292721-8	1993	When exposed to 0.1 microgram/ml t-PA clots formed from plasma containing 0.5-2 IU/ml of Fraxiparine, Reviparine and Enoxaparine showed only a minor increase in lysis rates compared to control clots.	Enoxaparin	117-128	plasminogen activator, tissue type	Homo sapiens	33-37
1329919-10	1992	As Enoxaparin moderated the generation of endogenous thrombin-antithrombin III after elective knee surgery, inhibition of prothrombin activation in vivo by Enoxaparin may be important for its prophylactic antithrombotic effect.	Enoxaparin	156-166	coagulation factor II, thrombin	Homo sapiens	53-61
1329253-0	1992	Enoxaparin (Clexane, Lovenox), a low molecular weight heparin, enhances t-PA-induced coronary thrombus lysis in anesthetized dogs without inducing hypocoagulability.	Enoxaparin	0-10	tissue-type plasminogen activator	Canis lupus familiaris	72-76
1325683-2	1992	We compared the influence of enoxaparin on the generation of thrombin in plasma to that of the eight fractions.	Enoxaparin	29-39	coagulation factor II, thrombin	Homo sapiens	61-69
1329253-15	1992	Its mechanism may be the significant elevation of plasma t-PA activity produced by both heparin and enoxaparin during t-PA infusion.	Enoxaparin	100-110	tissue-type plasminogen activator	Canis lupus familiaris	57-61
1329253-15	1992	Its mechanism may be the significant elevation of plasma t-PA activity produced by both heparin and enoxaparin during t-PA infusion.	Enoxaparin	100-110	tissue-type plasminogen activator	Canis lupus familiaris	118-122
1329253-0	1992	Enoxaparin (Clexane, Lovenox), a low molecular weight heparin, enhances t-PA-induced coronary thrombus lysis in anesthetized dogs without inducing hypocoagulability.	Enoxaparin	12-19	tissue-type plasminogen activator	Canis lupus familiaris	72-76
1329253-0	1992	Enoxaparin (Clexane, Lovenox), a low molecular weight heparin, enhances t-PA-induced coronary thrombus lysis in anesthetized dogs without inducing hypocoagulability.	Enoxaparin	21-28	tissue-type plasminogen activator	Canis lupus familiaris	72-76
1329253-7	1992	In dogs treated with t-PA associated to either heparin or enoxaparin, the thrombus weight was smaller (decreases of 34% and 44% respectively) than in animals given t-PA alone.	Enoxaparin	58-68	tissue-type plasminogen activator	Canis lupus familiaris	21-25
1329253-8	1992	The plasma amidolytic activity, expressed as t-PA activity, was greater 15 min after the beginning of t-PA infusion, in dogs pretreated with either heparin or enoxaparin than in animals given t-PA alone.	Enoxaparin	159-169	tissue-type plasminogen activator	Canis lupus familiaris	45-49
1963020-3	1990	However, the concentration of enoxaparin, measured by competitive binding assay, declined with the longer half-life of 60 min, and its anti-Factor IIa and anti-Factor Xa activities had half-lives of 40 and 275 min, respectively.	Enoxaparin	30-40	coagulation factor X	Homo sapiens	160-169
1651568-2	1991	To address this controversy, we examined the effects of standard and low molecular weight heparin (enoxaparine) on both t-PA induced clot lysis and t-PA mediated fibrinogenolysis in a human plasma system.	Enoxaparin	99-110	chromosome 20 open reading frame 181	Homo sapiens	120-124
1848441-8	1991	The anti Xa activity peak seen after adding AT III to plasma was much higher with heparin than with enoxaparin.	Enoxaparin	100-110	serpin family C member 1	Homo sapiens	44-50
1848441-9	1991	In urine, biological activities, measured with AT III supplementation, were higher with enoxaparin than with heparin.	Enoxaparin	88-98	serpin family C member 1	Homo sapiens	47-53
1658968-0	1991	Anti Xa activity and prothrombinase inhibition in patients treated with two different doses of enoxaparin in gynecologic surgery.	Enoxaparin	95-105	coagulation factor X	Homo sapiens	21-35
1658968-12	1991	The mechanism of intrinsic prothrombinase inhibition during prophylactic treatment with enoxaparin requires further investigation.	Enoxaparin	88-98	coagulation factor X	Homo sapiens	27-41
2166377-4	1990	Subcutaneous administration of 20 mg or 40 mg enoxaparin was followed by a barely significant (p less than 0.05) rise in aPTT (only at the higher dosage) and thrombin time four hours after injection.	Enoxaparin	46-56	coagulation factor II, thrombin	Homo sapiens	158-166
1963020-4	1990	These data may reflect more rapid clearance of longer chain molecules with anti-Factor IIa activity, or release by enoxaparin of an endogenous compound with anti-Factor Xa activity.	Enoxaparin	115-125	coagulation factor X	Homo sapiens	162-171
34884411-11	2021	Enoxaparin efficacy is reduced in severe NS and the dose should be adjusted to ideal body weight to achieve target anti-FXa activity.	Enoxaparin	0-10	coagulation factor X	Homo sapiens	120-123
25525049-4	2015	Production of tissue factor pathway inhibitor (TFPI), a physiologic heparin-induced inhibitor of tissue factor-induced coagulation that was used as a functional readout of biological activity of enoxaparins in these assays, was heightened in the presence of branded enoxaparin complexes, but its levels were variable in cultures treated with complexes containing US-generic enoxaparins.	Enoxaparin	195-206	tissue factor pathway inhibitor	Homo sapiens	14-45
25525049-4	2015	Production of tissue factor pathway inhibitor (TFPI), a physiologic heparin-induced inhibitor of tissue factor-induced coagulation that was used as a functional readout of biological activity of enoxaparins in these assays, was heightened in the presence of branded enoxaparin complexes, but its levels were variable in cultures treated with complexes containing US-generic enoxaparins.	Enoxaparin	195-206	tissue factor pathway inhibitor	Homo sapiens	47-51
25525049-4	2015	Production of tissue factor pathway inhibitor (TFPI), a physiologic heparin-induced inhibitor of tissue factor-induced coagulation that was used as a functional readout of biological activity of enoxaparins in these assays, was heightened in the presence of branded enoxaparin complexes, but its levels were variable in cultures treated with complexes containing US-generic enoxaparins.	Enoxaparin	195-205	tissue factor pathway inhibitor	Homo sapiens	14-45
25525049-4	2015	Production of tissue factor pathway inhibitor (TFPI), a physiologic heparin-induced inhibitor of tissue factor-induced coagulation that was used as a functional readout of biological activity of enoxaparins in these assays, was heightened in the presence of branded enoxaparin complexes, but its levels were variable in cultures treated with complexes containing US-generic enoxaparins.	Enoxaparin	195-205	tissue factor pathway inhibitor	Homo sapiens	47-51
25525049-4	2015	Production of tissue factor pathway inhibitor (TFPI), a physiologic heparin-induced inhibitor of tissue factor-induced coagulation that was used as a functional readout of biological activity of enoxaparins in these assays, was heightened in the presence of branded enoxaparin complexes, but its levels were variable in cultures treated with complexes containing US-generic enoxaparins.	Enoxaparin	374-385	tissue factor pathway inhibitor	Homo sapiens	14-45
25525049-4	2015	Production of tissue factor pathway inhibitor (TFPI), a physiologic heparin-induced inhibitor of tissue factor-induced coagulation that was used as a functional readout of biological activity of enoxaparins in these assays, was heightened in the presence of branded enoxaparin complexes, but its levels were variable in cultures treated with complexes containing US-generic enoxaparins.	Enoxaparin	374-385	tissue factor pathway inhibitor	Homo sapiens	47-51
25525049-5	2015	Analytical analyses suggest that the heightened immunostimulatory potential of some of the US-generic enoxaparin product lots could be tied to their capacity to form ultra-large and/or more stable complexes with PF4 than the other LMWHs included in this study.	Enoxaparin	102-112	platelet factor 4	Homo sapiens	212-215
11372675-5	2001	However, the AUC of released free TFPI significantly increased in the order: enoxaparin < UFH < certoparin < HF, showing MW dependency with the exception of UFH.	Enoxaparin	77-87	tissue factor pathway inhibitor	Homo sapiens	34-38
34524525-7	2022	RESULTS: Enoxaparin (2000 AXaIU/kg) not only profoundly increased the trabecular separation, but also notably decreased the trabecular bone volume/tissue volume, trabecular thickness, trabecular number and OCN level, in vivo.	Enoxaparin	9-19	bone gamma-carboxyglutamate protein	Rattus norvegicus	206-209
34524525-11	2022	Most importantly, inducing significant decreases of OCN/Runx2 mRNA/protein expression and formation of mineralized nodules by enoxaparin (0.1, 1.0 and 10 AXaIU/ml) were observed compared with the control group.	Enoxaparin	126-136	bone gamma-carboxyglutamate protein	Rattus norvegicus	52-55
34524525-11	2022	Most importantly, inducing significant decreases of OCN/Runx2 mRNA/protein expression and formation of mineralized nodules by enoxaparin (0.1, 1.0 and 10 AXaIU/ml) were observed compared with the control group.	Enoxaparin	126-136	RUNX family transcription factor 2	Rattus norvegicus	56-61
34524525-12	2022	While the notable decreases of BMP2 mRNA/protein level were only detected in enoxaparin (10 AXaIU/ml) group.	Enoxaparin	77-87	bone morphogenetic protein 2	Rattus norvegicus	31-35
34402789-7	2021	The 95% CI of the ratios of the geometric least squared means of anti-FXa activity was 96.28 - 102.65 IU/mL for Cmax and 100.67 - 105.15 hxIU/mL for the AUC0-t of Chemi Enoxaparin compared with those of Clexane, and for anti-FIIa activity, they were 86.65 - 96.73 IU/mL for the Cmax and 87.72 - 97.25 hxIU/mL AUC0-t, which met the criterion for bioequivalence.	Enoxaparin	169-179	coagulation factor X	Homo sapiens	70-73
34781984-0	2021	Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19.	Enoxaparin	35-45	coagulation factor X	Homo sapiens	55-64
34781984-2	2021	Dosing of Low Molecular Weight Heparin (LMWH) for thromboprophylaxis in patients with severe COVID-19 is subject to ongoing debate.In this brief report, we describe our study where we retrospectively examined the efficacy of standard- versus intermediate-dosing of enoxaparin in attaining and maintaining accepted prophylactic levels of anti-Factor Xa (anti-FXa) in critically ill patients with COVID-19.We collected data for all patients with confirmed COVID-19 who were treated with enoxaparin for thromboprophylaxis in a single Intensive Care Unit (ICU) in the United Kingdom between 31st March and 16th November 2020.	Enoxaparin	265-275	coagulation factor X	Homo sapiens	342-351
34781984-2	2021	Dosing of Low Molecular Weight Heparin (LMWH) for thromboprophylaxis in patients with severe COVID-19 is subject to ongoing debate.In this brief report, we describe our study where we retrospectively examined the efficacy of standard- versus intermediate-dosing of enoxaparin in attaining and maintaining accepted prophylactic levels of anti-Factor Xa (anti-FXa) in critically ill patients with COVID-19.We collected data for all patients with confirmed COVID-19 who were treated with enoxaparin for thromboprophylaxis in a single Intensive Care Unit (ICU) in the United Kingdom between 31st March and 16th November 2020.	Enoxaparin	265-275	coagulation factor X	Homo sapiens	358-361
34696334-18	2021	We report the case of a COVID-19 patient who, after administration of enoxaparin developed DIC secondary to virosis and positivity for platelet factor 4 (PF4) and a case of Long-COVID with high residual cardiovascular risk and persistence of blood chemistry of inflammation and procoagulative state.	Enoxaparin	70-80	platelet factor 4	Homo sapiens	154-157
34620636-0	2021	Enoxaparin-induced Wunderlich syndrome in a young patient with anti-GAD 65-associated opsoclonus and limbic encephalitis: a rare complication in a rare disease.	Enoxaparin	0-10	glutamate decarboxylase 2	Homo sapiens	68-74
34620636-2	2021	Our case of anti-GAD65-associated autoimmune encephalitis (AE), aged 30 years, developed this complication following use of enoxaparin and was managed by selective glue embolisation of subsegmental branches of right renal cortical arteries.	Enoxaparin	124-134	glutamate decarboxylase 2	Homo sapiens	17-22
34733033-0	2021	Factor Xa Levels in Patients Receiving Prophylactic Enoxaparin Sodium in the Intensive Care Unit of an Academic Hospital.	Enoxaparin	52-69	coagulation factor X	Homo sapiens	0-9
34733033-1	2021	Background: The aim of this study was to determine the anti-factor Xa levels in patients receiving enoxaparin sodium for venous thromboembolism prophylaxis in the intensive care unit (ICU).	Enoxaparin	99-116	coagulation factor X	Homo sapiens	60-69
34733033-9	2021	Conclusion: A fixed prophylactic 40 mg dose of enoxaparin was associated with a high proportion of subprophylactic anti-factor Xa levels.	Enoxaparin	47-57	coagulation factor X	Homo sapiens	120-129
34733033-11	2021	How to cite this article: Baloo MM, Scribante J, Perrie H, Calleemalay D, Omar S. Factor Xa Levels in Patients Receiving Prophylactic Enoxaparin Sodium in the Intensive Care Unit of an Academic Hospital.	Enoxaparin	134-151	coagulation factor X	Homo sapiens	82-91
34790076-3	2021	This case report describes a critically ill premature infant with a progressive, occlusive inferior vena cava thrombus who received supplemental ATIII during enoxaparin treatment.	Enoxaparin	158-168	serpin family C member 1	Homo sapiens	145-150
34078133-1	2021	BACKGROUND: Recommended prophylactic doses of enoxaparin (Lovenox) are associated with subprophylactic anti-Factor Xa (anti-Xa) levels.	Enoxaparin	46-56	coagulation factor X	Homo sapiens	108-117
34078133-1	2021	BACKGROUND: Recommended prophylactic doses of enoxaparin (Lovenox) are associated with subprophylactic anti-Factor Xa (anti-Xa) levels.	Enoxaparin	58-65	coagulation factor X	Homo sapiens	108-117
35440617-0	2022	Author Correction: Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19.	Enoxaparin	19-29	serpin family A member 1	Homo sapiens	39-58
35440617-0	2022	Author Correction: Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19.	Enoxaparin	19-29	transmembrane serine protease 2	Homo sapiens	73-80
35338216-0	2022	Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19.	Enoxaparin	0-10	serpin family A member 1	Homo sapiens	20-39
35454088-3	2022	On the other hand, experimental studies in transgenic mouse models have shown that treatment with enoxaparin significantly reduces cortical Abeta levels, as well as decreases the number of activated astrocytes around Abeta plaques.	Enoxaparin	98-108	amyloid beta (A4) precursor protein	Mus musculus	140-145
35454088-3	2022	On the other hand, experimental studies in transgenic mouse models have shown that treatment with enoxaparin significantly reduces cortical Abeta levels, as well as decreases the number of activated astrocytes around Abeta plaques.	Enoxaparin	98-108	amyloid beta (A4) precursor protein	Mus musculus	217-222
35338216-0	2022	Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19.	Enoxaparin	0-10	transmembrane serine protease 2	Homo sapiens	54-61
35338216-6	2022	Enoxaparin enhanced AAT inhibition of both TMPRSS2 activity and infection of hAEc with HCoV-229E.	Enoxaparin	0-10	serpin family A member 1	Homo sapiens	20-23
35338216-6	2022	Enoxaparin enhanced AAT inhibition of both TMPRSS2 activity and infection of hAEc with HCoV-229E.	Enoxaparin	0-10	transmembrane serine protease 2	Homo sapiens	43-50
35269938-5	2022	The inhibition of physiological and purified recombinant furin by screening selected compounds, Clexane, and these drugs in combination with CMK was assayed in fluorogenic tests by using a specific furin substrate.	Enoxaparin	96-103	furin, paired basic amino acid cleaving enzyme	Homo sapiens	57-62
35269938-8	2022	In fluorogenic assays, these two compounds and Clexane inhibited both physiological and recombinant furin in a dose-dependent way.	Enoxaparin	47-54	furin, paired basic amino acid cleaving enzyme	Homo sapiens	100-105
35269938-10	2022	In conclusion, we identified Kukoamine A, Zeaxanthin, and Clexane as new furin inhibitors.	Enoxaparin	58-65	furin, paired basic amino acid cleaving enzyme	Homo sapiens	73-78
33566465-0	2021	Age-Dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-Associated Thrombosis in Critically Ill Children: A Post Hoc Analysis of a Bayesian Phase 2b Randomized Clinical Trial.	Enoxaparin	64-74	renin binding protein	Homo sapiens	0-3
35100448-1	2022	OBJECTIVE: To evaluate the effectiveness of a body mass index (BMI)-based enoxaparin prophylaxis dosing protocol at achieving target anti-factor Xa (anti-Xa) concentrations in the trauma population.	Enoxaparin	74-84	coagulation factor X	Homo sapiens	138-147
2556813-0	1989	The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement.	Enoxaparin	89-100	coagulation factor X	Homo sapiens	30-39
2556813-8	1989	These findings suggest that when enoxaparine is administered as a once daily subcutaneous injection, the 12 hour anti-factor Xa level should not exceed 0.2 units per ml to minimize bleeding and levels greater than 0.05 units per ml should be obtained to optimize efficacy.	Enoxaparin	33-44	coagulation factor X	Homo sapiens	118-127
33892160-4	2021	METHODS: Gastric cancer patients who underwent gastrectomy received enoxaparin for 3 days from postoperative day (POD) 1 to 4.	Enoxaparin	68-78	coronin 7	Homo sapiens	95-125
33872443-8	2021	MIS-C patients (50%) received enoxaparin thromboprophylaxis (in addition to aspirin) with significant improvement in their inflammatory and ROTEM parameters upon outpatient follow up; none developed symptomatic thrombosis.	Enoxaparin	30-40	anti-Mullerian hormone	Homo sapiens	0-3
35338216-8	2022	In conclusion, enoxaparin enhances AAT inhibition of both TMPRSS2 and coronavirus infection.	Enoxaparin	15-25	serpin family A member 1	Homo sapiens	35-38
35338216-8	2022	In conclusion, enoxaparin enhances AAT inhibition of both TMPRSS2 and coronavirus infection.	Enoxaparin	15-25	transmembrane serine protease 2	Homo sapiens	58-65
34655821-0	2022	Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin.	Enoxaparin	123-133	coagulation factor X	Homo sapiens	23-32
33662380-7	2021	Enoxaparin induced PTPRsigma clustering, and counteracted PTPRsigma-mediated dephosphorylation of cortactin, which was shown to be important for inhibition of axonal regeneration.	Enoxaparin	0-10	cortactin	Rattus norvegicus	98-107
33566465-1	2021	OBJECTIVES: We explored the age-dependent heterogeneity in the efficacy of prophylaxis with enoxaparin against central venous catheter-associated deep venous thrombosis in critically ill children.	Enoxaparin	92-102	renin binding protein	Homo sapiens	28-31
33566465-14	2021	CONCLUSIONS: The relatively lesser contribution of thrombin generation on central venous catheter-associated thrombus formation in critically ill infants potentially explains the age-dependent heterogeneity in the efficacy of prophylaxis with enoxaparin.	Enoxaparin	243-253	renin binding protein	Homo sapiens	179-182
33545204-0	2021	Enoxaparin prevents CXCL16/ADAM10-mediated cisplatin renal toxicity: Role of the coagulation system and the transcriptional factor NF-kappaB.	Enoxaparin	0-10	chemokine (C-X-C motif) ligand 16	Mus musculus	20-26
33545204-0	2021	Enoxaparin prevents CXCL16/ADAM10-mediated cisplatin renal toxicity: Role of the coagulation system and the transcriptional factor NF-kappaB.	Enoxaparin	0-10	a disintegrin and metallopeptidase domain 10	Mus musculus	27-33
33545204-0	2021	Enoxaparin prevents CXCL16/ADAM10-mediated cisplatin renal toxicity: Role of the coagulation system and the transcriptional factor NF-kappaB.	Enoxaparin	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	131-140
33185785-5	2021	The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006).	Enoxaparin	48-58	C-reactive protein	Homo sapiens	159-177
33185785-5	2021	The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006).	Enoxaparin	48-58	C-reactive protein	Homo sapiens	179-182
33512867-0	2021	Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children.	Enoxaparin	0-10	coagulation factor X	Homo sapiens	86-95
33603528-10	2021	Furthermore, levels of CRP showed a decrease in patients treated with enoxaparin and fondaparinux, although the decrease in the fondaparinux group seems to be more relevant.	Enoxaparin	70-80	C-reactive protein	Homo sapiens	23-26
33567713-10	2021	Our data indicate that enoxaparin reduces endotoxin-augmented MV-induced diaphragmatic injury, partially through HIF-1alpha pathway inhibition.	Enoxaparin	23-33	hypoxia inducible factor 1, alpha subunit	Mus musculus	113-123
33093292-3	2021	AT-III and heparinoids such as enoxaparin (ENX) demonstrate potent anti-inflammatory activity, reducing organ injury and modulating leukocyte (LEU) activation, independent of their anticoagulant effect.	Enoxaparin	31-41	serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1	Mus musculus	0-6
33512867-2	2021	Several small retrospective studies have suggested that infants and young children require higher enoxaparin doses to achieve therapeutic anti-factor Xa levels compared with adults.	Enoxaparin	98-108	coagulation factor X	Homo sapiens	143-152
33512867-4	2021	The primary objective was to ascertain the enoxaparin dose required to achieve an anti-factor Xa level of 0.5 to 1.0 U/mL among 4 age groups in a large cohort of infants and young children between 60 days and 5 years of age.	Enoxaparin	43-53	coagulation factor X	Homo sapiens	87-96
33512867-7	2021	An inverse relationship between enoxaparin dose needed to achieve therapeutic anti-factor Xa levels and patient age was noted, particularly in the first year of life.	Enoxaparin	32-42	coagulation factor X	Homo sapiens	83-92
33512867-9	2021	CONCLUSION: Infants and young children require higher doses of enoxaparin to achieve therapeutic anti-factor Xa levels compared with adults.	Enoxaparin	63-73	coagulation factor X	Homo sapiens	102-111
32888192-12	2021	CONCLUSIONS: Enoxaparin thromboprophylaxis administered by CII inhibited more prominently FXa and preserved better the AT level, compared with standard subcutaneous care.	Enoxaparin	13-23	coagulation factor X	Homo sapiens	90-93
33400099-8	2021	Either weight-based or twice-daily escalated enoxaparin dosing regimens appear effective at achieving target anti-factor Xa levels among hospitalized patients, and no safety events were noted.	Enoxaparin	45-55	coagulation factor X	Homo sapiens	114-123
32888192-0	2021	Continuous intravenous infusion of enoxaparin controls thrombin formation more than standard subcutaneous administration in critically ill patients.	Enoxaparin	35-45	coagulation factor II, thrombin	Homo sapiens	55-63
33368089-5	2020	Surface plasmon resonance and circular dichroism spectroscopy demonstrate that heparin and enoxaparin, a low-molecular-weight heparin which is a clinical anticoagulant, bind and induce a conformational change in the spike (S1) protein receptor-binding domain (S1 RBD) of SARS-CoV-2.	Enoxaparin	91-101	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	216-221
33342267-6	2021	Factors associated with a higher dose of enoxaparin were male (96.8% vs. 3.2%, P < .01), younger age (39.5 vs. 52.7 years, P < .01), higher creatinine clearance (CrCl) (125.9 vs. 93.7 mL/min, P < .01), higher body surface area (2 m2 vs. 1.8 m2, P < .01), and higher injury severity score (18.4 vs. 10.8, P < .01).	Enoxaparin	41-51	CRCL	Homo sapiens	162-166
33342267-8	2021	On regression analysis, CrCl was the only independent predictor for higher enoxaparin dose.	Enoxaparin	75-85	CRCL	Homo sapiens	24-28
33342267-10	2021	CONCLUSION: Trauma patients who require higher enoxaparin doses to achieve prophylactic anti-Xa trough levels have a higher CrCl.	Enoxaparin	47-57	CRCL	Homo sapiens	124-128
33342267-11	2021	Patients with high CrCl may benefit from an initial higher dose of enoxaparin to achieve a target anti-Xa level in a shorter time interval to decrease VTE risk.	Enoxaparin	67-77	CRCL	Homo sapiens	19-23
33086312-0	2020	Low anti-Factor Xa level predicts 90-day Symptomatic Venous Thromboembolism in Surgical Patients Receiving Enoxaparin Prophylaxis: A Pooled Analysis of Eight Clinical Trials.	Enoxaparin	107-117	coagulation factor X	Homo sapiens	9-18
33171358-1	2020	BACKGROUND: It"s estimated that 40% to 60% of patients undergoing major orthopedic surgery of the hip or knee who do not receive thromboprophylaxis will develop deep venous thrombosis Instituto Nacional de Traumatologia e Ortopedia has established a guideline to prevent DVT with the administration of the Enoxaparin.	Enoxaparin	306-316	hedgehog interacting protein	Homo sapiens	98-101
32624425-3	2020	We sought to evaluate variability of anti-factor Xa levels in a cohort of RC patients receiving perioperative enoxaparin prophylaxis.	Enoxaparin	110-120	coagulation factor X	Homo sapiens	42-51
33155833-4	2020	Of the 245 patients included, 86 (35.1%) required enoxaparin at 30 mg to achieve the goal anti-factor Xa trough level.	Enoxaparin	50-60	coagulation factor X	Homo sapiens	95-104
33155833-5	2020	Factors associated with low dose enoxaparin were older age (59.6 vs. 46.2 years, P <= .01) and lower CrCl (81.5 mL/min vs. 93.7 mL/min, P <= .01).	Enoxaparin	33-43	CRCL	Homo sapiens	101-105
33155833-7	2020	A regression model determined that only CrCl predicted the need for low dose enoxaparin (adjusted odds ratio .982, 95% CI: .975-.990, P < .01).	Enoxaparin	77-87	CRCL	Homo sapiens	40-44
32578742-14	2020	We found that Bcl-2 was generally expressed at high levels in the enoxaparin group, while there was no difference in terms of Ki-67 between the groups.	Enoxaparin	66-76	BCL2 apoptosis regulator	Homo sapiens	14-19
32231825-0	2020	Enoxaparin Effect on Pregnancy Outcomes in a Patient with Elevated Plasminogen Activator Inhibitor-1.	Enoxaparin	0-10	serpin family E member 1	Homo sapiens	67-100
32421278-6	2020	Comparison of initial HIF-1? and troponin levels in intermediate high-risk PE patients given thrombolytic therapy and those treated with enoxaparin sodium showed that HIF-1? levels were significantly higher in the group that received thrombolytic therapy (p = 0.001), while there was no difference in troponin levels (p = 0.146).	Enoxaparin	137-154	hypoxia inducible factor 1 subunit alpha	Homo sapiens	167-173
32045583-6	2020	The primary study outcome was peak anti-factor Xa levels in response to fixed or weight-tiered enoxaparin.	Enoxaparin	95-105	coagulation factor X	Homo sapiens	40-49
32543247-1	2021	A novel enoxaparin regimen consisting of intra-arterial bolus (0.75 mg/kg) followed by intravenous infusion (0.75 mg/kg/6 hours) has been developed as a possible solution to the delayed absorption of oral P2Y12 inhibitors in opiate-treated ST-elevation myocardial infarction (STEMI) patients undergoing primary angioplasty.	Enoxaparin	8-18	purinergic receptor P2Y12	Homo sapiens	205-210
32730524-0	2020	[Cerebral sinovenous thrombosis in a newborn with mutation of MTHFR C677T treated with enoxaparin].	Enoxaparin	87-97	methylenetetrahydrofolate reductase	Homo sapiens	62-67
32353952-9	2020	Endotoxin-induced augmentation of VILI and epithelial apoptosis were reduced in the HIF-1alpha-deficient mice and in the wild-type mice following enoxaparin administration (p < 0.05).	Enoxaparin	146-156	hypoxia inducible factor 1, alpha subunit	Mus musculus	84-94
32353952-10	2020	Our data suggest that enoxaparin reduces endotoxin-augmented MV-induced ALI, partially by inhibiting the HIF-1alpha pathway.	Enoxaparin	22-32	hypoxia inducible factor 1, alpha subunit	Mus musculus	105-115
32268047-7	2020	Of the haematoma group, three patients (75%) received post-operative enoxaparin (p=0.166).	Enoxaparin	69-79	solute carrier family 35 member G1	Homo sapiens	54-58
32391762-12	2020	Early initiation of enoxaparin anti-factor Xa assay-guided venous thromboembolism chemoprophylaxis has a comparable risk of ICH progression to fixed dosing in patients with TBI.	Enoxaparin	20-30	coagulation factor X	Homo sapiens	36-45
31758517-13	2020	A significant decrease in platelet activation through COX1 (also known as prostaglandin G/H synthase 1) was observed with enoxaparin, but no significant differences in platelet function were observed with dabigatran.	Enoxaparin	122-132	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	54-58
31843692-0	2020	Prophylactic Enoxaparin Adjusted by Anti-Factor Xa Peak Levels Compared with Recommended Thromboprophylaxis and Rates of Clinically Evident Venous Thromboembolism in Surgical Oncology Patients.	Enoxaparin	13-23	coagulation factor X	Homo sapiens	41-50
31986476-7	2020	Compared to healthy volunteers, trauma patients had lower levels of AT, elevated thrombin generation, and lower anti-FXa levels in response to enoxaparin.	Enoxaparin	143-153	coagulation factor X	Homo sapiens	117-120
31986476-9	2020	We found that supplementation with AT, but not plasma, increased AT levels and improved enoxaparin-mediated inhibition of thrombin generation.	Enoxaparin	88-98	coagulation factor II, thrombin	Homo sapiens	122-130
31986476-0	2020	Supplementation with antithrombin III ex vivo optimizes enoxaparin responses in critically injured patients.	Enoxaparin	56-66	serpin family C member 1	Homo sapiens	21-37
31758517-13	2020	A significant decrease in platelet activation through COX1 (also known as prostaglandin G/H synthase 1) was observed with enoxaparin, but no significant differences in platelet function were observed with dabigatran.	Enoxaparin	122-132	prostaglandin-endoperoxide synthase 1	Homo sapiens	74-102
31618337-15	2019	Caspase-3 immunohistochemistry results also revealed that pre-treatment with enoxaparin gave better results in an IR-induced rat injury model.	Enoxaparin	77-87	caspase 3	Rattus norvegicus	0-9
32559127-0	2020	Anti-Factor Xa Levels in Low-weight Surgical Patients Receiving Enoxaparin for Venous Thromboembolism Prophylaxis: A Prospective Cohort Study.	Enoxaparin	64-74	coagulation factor X	Homo sapiens	5-14
32559127-3	2020	This study aimed to determine the rate of achieving a prophylactic peak anti-factor Xa (AFXa) level in low-weight surgical patients using enoxaparin 30 mg daily.	Enoxaparin	138-148	coagulation factor X	Homo sapiens	77-86
31463801-12	2020	CONCLUSIONS: Our dosing scheme of 40 mg vs. 60 mg enoxaparin stratified according to BMI proved to be effective in reaching prophylactic anti-FXa activity in 83% of adolescent patients.	Enoxaparin	50-60	coagulation factor X	Homo sapiens	142-145
31116389-0	2019	Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics.	Enoxaparin	95-105	coagulation factor X	Homo sapiens	19-28
31570424-0	2019	Inhibition of PAR-1 Receptor Signaling by Enoxaparin Reduces Cell Proliferation and Migration in A549 Cells.	Enoxaparin	42-52	Prader Willi/Angelman region RNA 1	Homo sapiens	14-19
31570424-7	2019	Following PAR-1 gene knock down, enoxaparin"s effect on A549 cell proliferation was diminished compared to scrambled siRNA.	Enoxaparin	33-43	Prader Willi/Angelman region RNA 1	Homo sapiens	10-15
31570424-8	2019	Our experiments verified that enoxaparin-mediated down-regulation of MAPK and PI3K, reduced MMP-2 expression and inhibited A549 cell migration.	Enoxaparin	30-40	mitogen-activated protein kinase 3	Homo sapiens	69-73
31570424-8	2019	Our experiments verified that enoxaparin-mediated down-regulation of MAPK and PI3K, reduced MMP-2 expression and inhibited A549 cell migration.	Enoxaparin	30-40	matrix metallopeptidase 2	Homo sapiens	92-97
31570424-10	2019	CONCLUSION: Results suggest that the anticancer activity of enoxaparin in A549 cells was mediated by the interference of two major PAR-1 downstream signaling pathways, MAPK/ERK and PI3K/Akt, which in turn inhibit proliferation and migration.	Enoxaparin	60-70	Prader Willi/Angelman region RNA 1	Homo sapiens	131-136
31570424-10	2019	CONCLUSION: Results suggest that the anticancer activity of enoxaparin in A549 cells was mediated by the interference of two major PAR-1 downstream signaling pathways, MAPK/ERK and PI3K/Akt, which in turn inhibit proliferation and migration.	Enoxaparin	60-70	mitogen-activated protein kinase 3	Homo sapiens	168-172
31570424-10	2019	CONCLUSION: Results suggest that the anticancer activity of enoxaparin in A549 cells was mediated by the interference of two major PAR-1 downstream signaling pathways, MAPK/ERK and PI3K/Akt, which in turn inhibit proliferation and migration.	Enoxaparin	60-70	mitogen-activated protein kinase 3	Homo sapiens	173-176
31570424-10	2019	CONCLUSION: Results suggest that the anticancer activity of enoxaparin in A549 cells was mediated by the interference of two major PAR-1 downstream signaling pathways, MAPK/ERK and PI3K/Akt, which in turn inhibit proliferation and migration.	Enoxaparin	60-70	AKT serine/threonine kinase 1	Homo sapiens	186-189
30989803-0	2019	Safety and effectiveness of aspirin and enoxaparin for venous thromboembolism prophylaxis after total hip and knee arthroplasty: a systematic review.	Enoxaparin	40-50	hedgehog interacting protein	Homo sapiens	102-105
30698331-0	2019	An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.	Enoxaparin	53-63	coagulation factor X	Homo sapiens	96-105
31112313-4	2019	OBJECTIVE: To evaluate peak anti-factor Xa (aFXa) levels in low-weight patients receiving enoxaparin for VTE prophylaxis.	Enoxaparin	90-100	coagulation factor X	Homo sapiens	33-42
30698331-1	2019	INTRODUCTION: Co-administration of enoxaparin and a direct oral factor Xa inhibitor (xabans: apixaban, edoxaban, rivaroxaban) could give rise to the problem of overlapping the anti-Xa activity when measuring direct oral anticoagulant (DOAC) levels.	Enoxaparin	35-45	coagulation factor X	Homo sapiens	64-73
30262570-10	2019	The 5-year event-free survival was 80.9+-2.2% among patients assigned to antithrombin compared to 85.9+-2.0% in the unfractionated heparin group (P=0.06), and 86.2+-2.0% in the enoxaparin group (P=0.10).	Enoxaparin	177-187	serpin family C member 1	Homo sapiens	73-85
30463865-2	2018	SUMMARY: A 52-year-old woman was treated with levetiracetam and prophylactic enoxaparin while receiving TPE to manage respiratory failure due to anti-MDA5 antibody-associated interstitial lung disease (ILD) with dermatomyositis.	Enoxaparin	77-87	interferon induced with helicase C domain 1	Homo sapiens	150-154
30713119-9	2019	Target endogenous thrombin potential reduction from baseline was more frequently obtained in the enoxaparin group versus UFH (50% versus 27.7%, respectively; P = .12).	Enoxaparin	97-107	coagulation factor II, thrombin	Homo sapiens	18-26
30472585-5	2019	The lower molecular weight of enoxaparin reduces the risk of HITT by binding to less PF4.	Enoxaparin	30-40	platelet factor 4	Homo sapiens	85-88
30472585-6	2019	To detect the binding capacity between enoxaparin and PF4 could be an effect way to control this risk before it goes to patients.	Enoxaparin	39-49	platelet factor 4	Homo sapiens	54-57
30472585-7	2019	In this work, a size exclusion chromatography (SEC) method was developed to analyze the patterns of complexes formed between PF4 and enoxaparin.	Enoxaparin	133-143	platelet factor 4	Homo sapiens	125-128
30472585-12	2019	It is a robust, accurate and practicable method, and provides an easy way to monitor the capacity of enoxaparin forming complexes with PF4, suggesting the HITT related quality of enoxaparin.	Enoxaparin	101-111	platelet factor 4	Homo sapiens	135-138
30855492-3	2019	PATIENT CONCERNS: A sixty-one-year-old male was diagnosed with thymoma with PRCA after he complained fatigue, tinnitus, and weakness for 1 month, he received therapy with recombinant erythropoietin (rhEPO) for 1 month after the tumor was totally resected and readmitted with pulmonary embolism and received anticoagulation therapy with enoxaparin for 3 months.	Enoxaparin	336-346	erythropoietin	Homo sapiens	183-197
29626461-2	2018	Enoxaparin"s pharmacologic impact can be quantified by using anti-Factor Xa (aFXa) levels.	Enoxaparin	0-10	coagulation factor X	Homo sapiens	66-75
30198315-10	2018	The TFPI levels returned to baseline levels by 6 hours in ovine LMWH-treated animals but remained slightly elevated in animals treated with branded enoxaparin.	Enoxaparin	148-158	tissue factor pathway inhibitor	Homo sapiens	4-8
29958743-2	2018	Considering his clinical stability and sPESI 0, enoxaparin 1 mg/kg BID was started for 24 h, and the patient was then considered for early discharge with apixaban 10 mg BID.	Enoxaparin	48-58	BH3 interacting domain death agonist	Homo sapiens	67-70
28736059-0	2018	Anti-Factor Xa measurements in acute care surgery patients to examine enoxaparin dose.	Enoxaparin	70-80	coagulation factor X	Homo sapiens	5-14
30181723-0	2018	Effect of Exogenous Antithrombin Administration on Anti-Xa Levels in Infants Treated With Enoxaparin.	Enoxaparin	90-100	serpin family C member 1	Homo sapiens	20-32
29658328-0	2018	Effects of Enoxaparin on Intravascular Sclerostin Release in Healthy Men.	Enoxaparin	11-21	sclerostin	Homo sapiens	39-49
29658328-7	2018	The percentage of increase (Delta) in plasma Scl after 10 minutes was directly correlated with enoxaparin dose per kg/m2 of body mass index (rho = 0.587, P = .017) and strongly inversely correlated with the preinjection Scl levels (rho = -0.747, P = .0008).	Enoxaparin	95-105	sclerostin	Homo sapiens	45-48
29658328-10	2018	This study shows that enoxaparin has a stimulating effect on the intravascular release of calcification inhibitor Scl in healthy men.	Enoxaparin	22-32	sclerostin	Homo sapiens	114-117
30181723-1	2018	OBJECTIVES: Determine the effect of exogenous antithrombin III administration on low molecular weight heparin anti-Xa levels in the context of enoxaparin dosing in infants.	Enoxaparin	143-153	serpin family C member 1	Homo sapiens	46-62
30181723-8	2018	The median dose of antithrombin III was 50 units/kg and was administered when patients were receiving a median enoxaparin dose of 1.71 mg/kg.	Enoxaparin	111-121	serpin family C member 1	Homo sapiens	19-35
30181723-10	2018	CONCLUSIONS: These results demonstrated that administration of exogenous antithrombin III to infants who were being treated with enoxaparin results in a significant increase in anti-Xa levels.	Enoxaparin	129-139	serpin family C member 1	Homo sapiens	73-89
30181723-12	2018	However, antithrombin III supplementation could be considered a potential option for patients who are unable to adequately achieve therapeutic anti-Xa levels with enoxaparin alone.	Enoxaparin	163-173	serpin family C member 1	Homo sapiens	9-25
29367044-0	2018	Trauma patients with lower extremity and pelvic fractures: Should anti-factor Xa trough level guide prophylactic enoxaparin dose?	Enoxaparin	113-123	coagulation factor X	Homo sapiens	71-80
29490713-9	2018	CONCLUSIONS: Enoxaparin doses required to achieve prophylactic anti-factor Xa concentrations in young children with CHD were consistently higher than the currently recommended prophylactic dosing regimens.	Enoxaparin	13-23	coagulation factor X	Homo sapiens	68-77
29930947-8	2018	The NCX antagonist KB-R7943 abolished the enoxaparin or ardeparin antiarrhythmic effects in isolated atria.	Enoxaparin	42-52	solute carrier family 8 member A1	Rattus norvegicus	4-7
29490713-0	2018	Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD.	Enoxaparin	30-40	coagulation factor X	Homo sapiens	89-98
29490713-2	2018	We aimed to determine whether current enoxaparin dosing regimens effectively achieve anti-factor Xa concentrations within prophylactic goal ranges in this patient population.	Enoxaparin	38-48	coagulation factor X	Homo sapiens	90-99
29367044-11	2018	CONCLUSIONS: Prophylactic enoxaparin adjusted by anti-factor Xa level may lead to a decreased rate of clinically evident VTE among trauma patients with lower extremity and/or pelvic fractures.	Enoxaparin	26-36	coagulation factor X	Homo sapiens	54-63
28703660-8	2017	Conclusion Treatment with low-dose aspirin, enoxaparin and folic acid was the most effective therapy in women with RM who carried a C677T MTHFR mutation.	Enoxaparin	44-54	methylenetetrahydrofolate reductase	Homo sapiens	138-143
29031112-8	2017	With the method, the molar percentage of the ATIII-binding site of enoxaparin from different batches and different manufactures were measured and compared.	Enoxaparin	67-77	serpin family C member 1	Homo sapiens	45-50
28156170-2	2017	In this study, enoxaparin (Enox)-albumin microspheres (Enox-Alb MS) were, optimally, developed as lung targeted sustained release MP for IV use.	Enoxaparin	15-25	albumin	Rattus norvegicus	60-63
28846877-0	2017	Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients.	Enoxaparin	95-105	coagulation factor X	Homo sapiens	12-15
28918992-0	2017	Anti-factor Xa levels in patients undergoing laparoscopic sleeve gastrectomy: 2 different dosing regimens of enoxaparin.	Enoxaparin	109-119	coagulation factor X	Homo sapiens	0-14
28918992-13	2017	However, a multivariate analysis including enoxaparin dose found that only enoxaparin dose remained significantly correlated with anti-FXa levels.	Enoxaparin	75-85	coagulation factor X	Homo sapiens	135-138
28846877-11	2017	CONCLUSIONS: Continuous infusion of enoxaparin led to lower anti-FXa Cmax24h than standard SCB administration.	Enoxaparin	36-46	coagulation factor X	Homo sapiens	65-68
28781584-6	2017	Lovenox 90 mg subcutaneous twice daily (1 mg/kg BID) was started together with warfarin to keep INR 2-3.	Enoxaparin	0-7	BH3 interacting domain death agonist	Homo sapiens	48-51
28425077-2	2017	We compared the effect of hemodialysis (HD) with enoxaparin as an anticoagulant and without systemic anticoagulation (heparin-grafted membrane-Evodial) on the release of monocyte chemoattractant protein 1 (MCP-1), endostatin (ES) and activin A (Act-A).	Enoxaparin	49-59	C-C motif chemokine ligand 2	Homo sapiens	170-204
28228055-14	2017	Weight-based enoxaparin dosing (0.5 mg/kg/dose BID) is an option in trauma patients considered to be at a lower risk of bleeding complications.	Enoxaparin	13-23	BH3 interacting domain death agonist	Homo sapiens	47-50
28808492-0	2017	Assessment of anti-factor Xa activity of enoxaparin for venous thromboembolism prophylaxis in morbidly obese surgical patients.	Enoxaparin	41-51	coagulation factor X	Homo sapiens	19-28
28467656-4	2017	At approved doses, estimated odds ratios vs. both doses of enoxaparin for the three FXa inhibitors (range: 0.35-0.75 for VTE; 0.76-1.09 for bleeding) compared with those for dabigatran (range: 0.66-1.21 for VTE; 1.10-1.38 for bleeding) suggested generally greater efficacy and less bleeding for the FXa inhibitors.	Enoxaparin	59-69	coagulation factor X	Homo sapiens	84-87
27546887-2	2017	Peripheral administration of enoxaparin (ENO) reportedly reduces the level of Abeta and the amyloid plaques in the cortex of amyloid precursor protein (APP) transgenic mice.	Enoxaparin	29-39	amyloid beta (A4) precursor protein	Mus musculus	125-150
27546887-2	2017	Peripheral administration of enoxaparin (ENO) reportedly reduces the level of Abeta and the amyloid plaques in the cortex of amyloid precursor protein (APP) transgenic mice.	Enoxaparin	41-44	amyloid beta (A4) precursor protein	Mus musculus	125-150
28282887-3	2017	In fact, a minimal chain length of 18 saccharides units, including an antithrombin (AT) binding pentasaccharide, is mandatory to form the active ternary complex for LMWH obtained by alkaline beta-elimination (e.g., enoxaparin).	Enoxaparin	215-225	serpin family C member 1	Homo sapiens	70-82
27609342-0	2017	The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.	Enoxaparin	47-57	coagulation factor II, thrombin	Homo sapiens	63-71
28221043-6	2017	111In-FGF-2 had affinity for the low-molecular-weight heparin enoxaparin identical to that of unlabeled FGF-2 (Kd: 0.6 +- 0.07 muM and 0.33 +- 0.03 muM, respectively) as assessed by isothermal titration calorimetry.	Enoxaparin	62-72	fibroblast growth factor 2	Mus musculus	6-11
27609342-7	2017	Then, the experimental model of thrombin generation was used to compare the inhibitory effect of clinically relevant concentrations of both tinzaparin and enoxaparin.	Enoxaparin	155-165	coagulation factor II, thrombin	Homo sapiens	32-40
28220880-5	2017	Parenteral administration of enoxaparin (FXa/IIa inhibitor) and fondaparinux (FXa inhibitor) over 14 days reduced to severity of aortic aneurysm and atherosclerosis in AngII-infused ApoE-/- mice.	Enoxaparin	29-39	ATPase, class II, type 9A	Mus musculus	45-48
28220880-5	2017	Parenteral administration of enoxaparin (FXa/IIa inhibitor) and fondaparinux (FXa inhibitor) over 14 days reduced to severity of aortic aneurysm and atherosclerosis in AngII-infused ApoE-/- mice.	Enoxaparin	29-39	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	168-173
28220880-5	2017	Parenteral administration of enoxaparin (FXa/IIa inhibitor) and fondaparinux (FXa inhibitor) over 14 days reduced to severity of aortic aneurysm and atherosclerosis in AngII-infused ApoE-/- mice.	Enoxaparin	29-39	apolipoprotein E	Mus musculus	182-186
27936527-0	2017	Individualized dosing of enoxaparin in a morbidly obese patient by monitoring the anti-factor Xa.	Enoxaparin	25-35	coagulation factor X	Homo sapiens	87-96
27693677-3	2016	Thereafter, enoxaparin was incorporated via hydrophobic ion pairing in the chosen SEDDS, which were evaluated regarding their mucus permeating properties, stability towards pancreatic lipase, drug release profile and cytotoxicity.	Enoxaparin	12-22	pancreatic lipase	Homo sapiens	173-190
29322808-8	2017	RESULTS: Neovascularisation, recanalization and macrophage accumulation were statistically significantly higher in the EGF+Enoxaparin group than the other groups (p &lt; 0.05), and the volume of thrombus was determined to be significantly lower.	Enoxaparin	123-133	epidermal growth factor like 1	Rattus norvegicus	119-122
29322808-10	2017	As for the thrombus resolution, statistically significant regress in the EGF+Enoxaparin group (p &lt; 0.05) compared to the other groups was found.	Enoxaparin	77-87	epidermal growth factor like 1	Rattus norvegicus	73-76
27256341-0	2016	The use of anti-factor Xa monitoring in a selection of patients receiving enoxaparin at a large academic medical center.	Enoxaparin	74-84	coagulation factor X	Homo sapiens	16-25
27466508-0	2016	Enoxaparin Attenuates Mouse Colon Cancer Liver Metastases by Inhibiting Heparanase and Interferon-gamma-inducible Chemokines.	Enoxaparin	0-10	interferon gamma	Mus musculus	87-103
27383732-0	2016	Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.	Enoxaparin	20-30	coagulation factor X	Homo sapiens	55-64
27383732-2	2016	The VTE rate when enoxaparin sodium is dosed by anti-factor Xa (anti-Xa) trough level is not well described.	Enoxaparin	18-35	coagulation factor X	Homo sapiens	53-62
27440463-0	2016	Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women.	Enoxaparin	10-20	coagulation factor X	Homo sapiens	46-49
26927051-3	2016	Thrombin also amplifies the response to the tissue injury, coagulation and platelet response, so the treatment of ACS is based on the combined use of both antiplatelet (such as aspirin, clopidogrel, prasugrel and ticagrelor) and antithrombotic drugs (unfractionated heparin, enoxaparin, fondaparinux and bivalirudin).	Enoxaparin	275-285	coagulation factor II, thrombin	Homo sapiens	0-8
26989119-6	2016	RESULTS: We demonstrate that enoxaparin, but not rivaroxaban, increases the migration potential of MSCs and increases their cell count in line with elevated mRNA expression of C-X-C chemokine receptor type 4 (CXCR4), tumor necrosis factor alpha (TNFalpha), and alpha-B-crystallin (CryaB).	Enoxaparin	29-39	C-X-C motif chemokine receptor 4	Homo sapiens	176-207
26989119-6	2016	RESULTS: We demonstrate that enoxaparin, but not rivaroxaban, increases the migration potential of MSCs and increases their cell count in line with elevated mRNA expression of C-X-C chemokine receptor type 4 (CXCR4), tumor necrosis factor alpha (TNFalpha), and alpha-B-crystallin (CryaB).	Enoxaparin	29-39	C-X-C motif chemokine receptor 4	Homo sapiens	209-214
26989119-6	2016	RESULTS: We demonstrate that enoxaparin, but not rivaroxaban, increases the migration potential of MSCs and increases their cell count in line with elevated mRNA expression of C-X-C chemokine receptor type 4 (CXCR4), tumor necrosis factor alpha (TNFalpha), and alpha-B-crystallin (CryaB).	Enoxaparin	29-39	tumor necrosis factor	Homo sapiens	217-244
26989119-6	2016	RESULTS: We demonstrate that enoxaparin, but not rivaroxaban, increases the migration potential of MSCs and increases their cell count in line with elevated mRNA expression of C-X-C chemokine receptor type 4 (CXCR4), tumor necrosis factor alpha (TNFalpha), and alpha-B-crystallin (CryaB).	Enoxaparin	29-39	tumor necrosis factor	Homo sapiens	246-254
26989119-6	2016	RESULTS: We demonstrate that enoxaparin, but not rivaroxaban, increases the migration potential of MSCs and increases their cell count in line with elevated mRNA expression of C-X-C chemokine receptor type 4 (CXCR4), tumor necrosis factor alpha (TNFalpha), and alpha-B-crystallin (CryaB).	Enoxaparin	29-39	crystallin alpha B	Homo sapiens	281-286
26945394-3	2016	In this study, we aimed to estimate serum (hepcidin) level in acute ischemic stroke (AIS) patients and to investigate whether subcutaneous enoxaparin sodium, which is a low-molecular-weight heparin (LMWH) derivative, could modulate serum hepcidin level in those patients.	Enoxaparin	139-156	hepcidin antimicrobial peptide	Homo sapiens	238-246
27083693-5	2016	Both NAC and enoxaparin led to a significant reduction in ovarian tissue 8-OHdG (P = 0.004 and P = 0.01, respectively) and MPO (P = 0.013 and P = 0.023, respectively) concentrations compared with I/R group, indicating a protective effect against I/R oxidative damage.	Enoxaparin	13-23	myeloperoxidase	Rattus norvegicus	123-126
26377606-0	2016	The Levels of Tissue Factor Pathway Inhibitor in Sepsis Patients Receiving Prophylactic Enoxaparin.	Enoxaparin	88-98	tissue factor pathway inhibitor	Homo sapiens	14-45
26377606-9	2016	In contrast, plasma levels of both total and free TFPI were markedly elevated and increased after enoxaparin therapy.	Enoxaparin	98-108	tissue factor pathway inhibitor	Homo sapiens	50-54
26758598-8	2016	The utility of this approach is demonstrated for tetrasaccharide SEC fractions of the low molecular weight heparin drug enoxaparin facilitating the isolation and characterization of an unsaturated 3-O-sulfated tetrasaccharide containing a portion of the antithrombin-III binding sequence.	Enoxaparin	120-130	serpin family C member 1	Homo sapiens	254-270
27693871-0	2016	Supratherapeutic anti-factor Xa levels in patients receiving prophylactic doses of enoxaparin: A case series.	Enoxaparin	83-93	coagulation factor X	Homo sapiens	22-31
26486415-0	2016	Elucidating the use of enoxaparin in non-ST-elevation acute coronary syndromes (NSTE-ACS).	Enoxaparin	23-33	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	85-88
27693871-2	2016	Real time anti-Factor Xa monitoring for surgical patients on enoxaparin prophylaxis is increasingly common.	Enoxaparin	61-71	coagulation factor X	Homo sapiens	15-24
27693871-3	2016	PRESENTATION OF CASES: We report on three cancer patients with therapeutic or supratherapeutic anti-Factor Xa levels while on prophylactic doses of enoxaparin after surgical procedures.	Enoxaparin	148-158	coagulation factor X	Homo sapiens	100-109
26280926-10	2015	These results were further confirmed by orthogonal analytical techniques, including NMR, which revealed compositional differences of oligosaccharides both in low- and high-affinity antithrombin fractions of enoxaparin.	Enoxaparin	207-217	serpin family C member 1	Homo sapiens	181-193
26489727-2	2015	To explore this possibility, the present study compared the capacity of the LMWH enoxaparin and the specific inhibitors of Xa (apixaban and fondaparinux) to inhibit thrombin generation triggered by pancreas adenocarcinoma cells (BXPC3) and human breast carcinoma cells (MCF7).	Enoxaparin	81-91	coagulation factor II, thrombin	Homo sapiens	165-173
26335350-9	2015	Afterwards, an affinity CE method was used to investigate the interactions of two proteins, namely HSA and vitronectin, with three ligands namely enoxaparin sodium, unfractionated heparin, and pentosan polysulfate sodium.	Enoxaparin	146-163	vitronectin	Homo sapiens	107-118
25738575-10	2015	Smaller fractions, in particular dp4 (four saccharide units), were responsible for the inhibitory effect of enoxaparin.	Enoxaparin	108-118	transcription factor Dp family member 3	Homo sapiens	33-36
26046354-7	2015	A disaccharide fraction of enoxaparin inhibited the release of IL-4, IL-5, IL-13 and TNF-alpha by more than 57% while a tetrasaccharide fraction was found to inhibit the release of tested cytokines by more than 68%.	Enoxaparin	27-37	interleukin 4	Homo sapiens	63-67
26046354-7	2015	A disaccharide fraction of enoxaparin inhibited the release of IL-4, IL-5, IL-13 and TNF-alpha by more than 57% while a tetrasaccharide fraction was found to inhibit the release of tested cytokines by more than 68%.	Enoxaparin	27-37	interleukin 5	Homo sapiens	69-73
26046354-7	2015	A disaccharide fraction of enoxaparin inhibited the release of IL-4, IL-5, IL-13 and TNF-alpha by more than 57% while a tetrasaccharide fraction was found to inhibit the release of tested cytokines by more than 68%.	Enoxaparin	27-37	interleukin 13	Homo sapiens	75-80
26046354-7	2015	A disaccharide fraction of enoxaparin inhibited the release of IL-4, IL-5, IL-13 and TNF-alpha by more than 57% while a tetrasaccharide fraction was found to inhibit the release of tested cytokines by more than 68%.	Enoxaparin	27-37	tumor necrosis factor	Homo sapiens	85-94
25716128-2	2015	The objective of this study was to assess anti-factor Xa activity in adolescent bariatric surgical patients receiving prophylactic enoxaparin.	Enoxaparin	131-141	coagulation factor X	Homo sapiens	47-56
26031274-2	2015	Presently, standard dose enoxaparin (30 mg BID) is used as chemical prophylaxis, regardless of weight or physiologic status.	Enoxaparin	25-35	BH3 interacting domain death agonist	Homo sapiens	43-46
25961885-0	2015	In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparin.	Enoxaparin	117-127	interleukin 6	Homo sapiens	24-28
25961885-0	2015	In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparin.	Enoxaparin	117-127	C-X-C motif chemokine ligand 8	Homo sapiens	33-37
25961885-3	2015	Our study indicated that enoxaparin inhibits the release of IL-6 and IL-8 from A549 pulmonary epithelial cells.	Enoxaparin	25-35	interleukin 6	Homo sapiens	60-64
25961885-3	2015	Our study indicated that enoxaparin inhibits the release of IL-6 and IL-8 from A549 pulmonary epithelial cells.	Enoxaparin	25-35	C-X-C motif chemokine ligand 8	Homo sapiens	69-73
25961885-13	2015	RESULTS: Enoxaparin (60 mug/mL) inhibited the release of IL-6 and IL-8 by &gt;30%.	Enoxaparin	9-19	interleukin 6	Homo sapiens	57-61
25961885-13	2015	RESULTS: Enoxaparin (60 mug/mL) inhibited the release of IL-6 and IL-8 by &gt;30%.	Enoxaparin	9-19	C-X-C motif chemokine ligand 8	Homo sapiens	66-70
25325764-3	2015	The drug of choice is enoxaparin, due to its favorable FXa/FIIa ratio and the availability of pharmacokinetic and pharmacodynamic data.	Enoxaparin	22-32	coagulation factor X	Homo sapiens	55-58
25396759-11	2015	Endogenous thrombin potential (ETP), unchanged with rivaroxaban, decreased significantly with enoxaparin; the maximal rising slope (mean velocity rate index) decreased more with rivaroxaban.	Enoxaparin	94-104	coagulation factor II, thrombin	Homo sapiens	11-19
25488183-0	2015	Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation.	Enoxaparin	0-10	dedicator of cytokinesis 1	Homo sapiens	86-91
25488183-0	2015	Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation.	Enoxaparin	0-10	vimentin	Homo sapiens	104-112
25488183-0	2015	Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation.	Enoxaparin	0-10	AKT serine/threonine kinase 1	Homo sapiens	134-137
25488183-10	2015	Additional enoxaparin administration resulted in better effective inhibition of Akt activity compared with gefitinib alone.	Enoxaparin	11-21	AKT serine/threonine kinase 1	Homo sapiens	80-83
25488183-14	2015	Our data indicate that enoxaparin sensitizes gefitinib antitumor and antimigration activity in lung cancer by suppressing DOCK1 expression, Akt activity, and vimentin phosphorylation.	Enoxaparin	23-33	dedicator of cytokinesis 1	Homo sapiens	122-127
25488183-14	2015	Our data indicate that enoxaparin sensitizes gefitinib antitumor and antimigration activity in lung cancer by suppressing DOCK1 expression, Akt activity, and vimentin phosphorylation.	Enoxaparin	23-33	AKT serine/threonine kinase 1	Homo sapiens	140-143
25488183-14	2015	Our data indicate that enoxaparin sensitizes gefitinib antitumor and antimigration activity in lung cancer by suppressing DOCK1 expression, Akt activity, and vimentin phosphorylation.	Enoxaparin	23-33	vimentin	Homo sapiens	158-166
25526009-1	2014	Enoxaparin sodium is a heparin of low molecular weight with antithrombotic properties that acts by inhibiting factor Xa.	Enoxaparin	0-17	coagulation factor X	Homo sapiens	110-119
25406658-0	2014	Changes in thrombin generation and D-dimer concentrations in women injecting enoxaparin during pregnancy and the puerperium.	Enoxaparin	77-87	coagulation factor II, thrombin	Homo sapiens	11-19
25406658-3	2014	The aim of this study is to describe thrombin generation changes and D-dimer concentrations in women injecting enoxaparin during pregnancy the postnatal period.	Enoxaparin	111-121	coagulation factor II, thrombin	Homo sapiens	37-45
25406658-4	2014	METHODS: One hundred and twenty-three women injecting enoxaparin had their thrombin generation, as measured by Calibrated Automated Thombinography (CAT), repeatedly assayed during pregnancy, once in each trimester, at delivery and 8 weeks post-partum.	Enoxaparin	54-64	coagulation factor II, thrombin	Homo sapiens	75-83
24837008-0	2014	Effects of enoxaparin on myeloperoxidase release during hemodialysis.	Enoxaparin	11-21	myeloperoxidase	Homo sapiens	25-40
24837008-2	2014	We studied if low-molecular-weight heparin enoxaparin administered for hemodialysis (HD) anticoagulation causes systemic MPO activation.	Enoxaparin	43-53	myeloperoxidase	Homo sapiens	121-124
24837008-3	2014	Plasma MPO levels were measured in patients undergoing maintenance HD with an intravenous bolus of enoxaparin.	Enoxaparin	99-109	myeloperoxidase	Homo sapiens	7-10
24837008-5	2014	During enoxaparin-anticoagulated HD plasma MPO levels strikingly increased in all patients (8.6-fold at 10 minutes and 3.3-fold at 120 minutes, both P &lt; 0.0001).	Enoxaparin	7-17	myeloperoxidase	Homo sapiens	43-46
24837008-8	2014	Enoxaparin administered for HD anticoagulation induces a marked and dose-dependent increase in plasma MPO as a plausibly favorable result of the liberation of the enzyme from the vascular wall.	Enoxaparin	0-10	myeloperoxidase	Homo sapiens	102-105
24996496-10	2014	The difference in the pre- and postoperative AMH levels was higher in the detorsion-only group than in the control and detorsion-enoxaparin groups.	Enoxaparin	129-139	anti-Mullerian hormone	Rattus norvegicus	45-48
25278813-2	2014	Moreover, enoxaparin increases the release of tissue factor pathway inhibitor, which inhibits coagulation activity.	Enoxaparin	10-20	tissue factor pathway inhibitor	Homo sapiens	46-77
24943261-7	2014	We evaluated how this change in anti-FXa assays influenced enoxaparin dosing (mg kg(-1) ).	Enoxaparin	59-69	coagulation factor X	Homo sapiens	37-40
24375987-0	2014	Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.	Enoxaparin	95-105	serpin family C member 1	Homo sapiens	28-44
24627228-10	2014	Counts for GFAP-expressing astrocytes were highest in the enoxaparin (p &lt; 0.001) and rt-PA (p &lt; 0.05)-treated groups.	Enoxaparin	58-68	glial fibrillary acidic protein	Rattus norvegicus	11-15
24375987-5	2014	PROCEDURE: This retrospective study compared time to therapeutic anti-Xa levels in patients &lt;1 year of age receiving enoxaparin with AT3 (Group 1) and without AT3 (Group 2) for treatment of thrombosis.	Enoxaparin	120-130	serpin family C member 1	Homo sapiens	136-139
24616065-3	2014	ACE is used in this work to measure the relative AT-III binding affinities of the low molecular weight heparins (LWMHs) dalteparin, enoxaparin, and tinzaparin and the synthetic pentasaccharide drug fondaparinux (Arixtra).	Enoxaparin	132-142	angiotensin I converting enzyme	Homo sapiens	0-3
23104956-2	2014	We aimed to compare the effect of unfractionated (UFH) and low-molecular-weight (LMWH enoxaparin) heparin used as anticoagulants during hemodialysis (HD) on plasma levels and relationships of OPG, soluble receptor activator of nuclear factor kappaB Ligand (sRANKL), and vWF.	Enoxaparin	86-96	TNF receptor superfamily member 11b	Homo sapiens	192-195
23104956-10	2014	After 10 minutes of HD, especially under enoxaparin use, a positive correlation between OPG and vWF increase was noticed (P = .03, R = .45).	Enoxaparin	41-51	TNF receptor superfamily member 11b	Homo sapiens	88-91
23104956-10	2014	After 10 minutes of HD, especially under enoxaparin use, a positive correlation between OPG and vWF increase was noticed (P = .03, R = .45).	Enoxaparin	41-51	von Willebrand factor	Homo sapiens	96-99
24616065-3	2014	ACE is used in this work to measure the relative AT-III binding affinities of the low molecular weight heparins (LWMHs) dalteparin, enoxaparin, and tinzaparin and the synthetic pentasaccharide drug fondaparinux (Arixtra).	Enoxaparin	132-142	serpin family C member 1	Homo sapiens	49-55
25237354-5	2014	SERUM CONCENTRATIONS OF SAA (P: 0.02), CRP (P: 0.02) and ferritin (P: 0.01) significantly reduced in heparin group during measurements compared to baseline, circulating levels of IL-6 (P: 0.002), SAA (P: 0.009), CRP (P: 0.01) were significantly decreased in enoxaparin group.	Enoxaparin	258-268	interleukin 6	Homo sapiens	179-183
24525311-10	2014	Additionally, enoxaparin decreased plasma TNF-alpha by 22% (P&lt;0.01), increased hepatic lipase (HL) activity by 81% (P&lt;0.01), along with a 2-fold increase in ISI (P&lt;0.01).	Enoxaparin	14-24	tumor necrosis factor	Homo sapiens	42-51
24525311-10	2014	Additionally, enoxaparin decreased plasma TNF-alpha by 22% (P&lt;0.01), increased hepatic lipase (HL) activity by 81% (P&lt;0.01), along with a 2-fold increase in ISI (P&lt;0.01).	Enoxaparin	14-24	lipase C, hepatic type	Homo sapiens	82-96
24525311-10	2014	Additionally, enoxaparin decreased plasma TNF-alpha by 22% (P&lt;0.01), increased hepatic lipase (HL) activity by 81% (P&lt;0.01), along with a 2-fold increase in ISI (P&lt;0.01).	Enoxaparin	14-24	lipase C, hepatic type	Homo sapiens	98-100
24525311-13	2014	CONCLUSIONS: The association of the effect on post-prandial metabolism, plasma TNFalpha level and HL activity during prolonged enoxaparin treatment may support the hypothesis that the beneficial outcome of enoxaparin may possibly be linked to anti-inflammatory and lipase-potentiating impact.	Enoxaparin	127-137	tumor necrosis factor	Homo sapiens	79-87
24525311-13	2014	CONCLUSIONS: The association of the effect on post-prandial metabolism, plasma TNFalpha level and HL activity during prolonged enoxaparin treatment may support the hypothesis that the beneficial outcome of enoxaparin may possibly be linked to anti-inflammatory and lipase-potentiating impact.	Enoxaparin	127-137	lipase C, hepatic type	Homo sapiens	98-100
24525311-13	2014	CONCLUSIONS: The association of the effect on post-prandial metabolism, plasma TNFalpha level and HL activity during prolonged enoxaparin treatment may support the hypothesis that the beneficial outcome of enoxaparin may possibly be linked to anti-inflammatory and lipase-potentiating impact.	Enoxaparin	206-216	tumor necrosis factor	Homo sapiens	79-87
24525311-13	2014	CONCLUSIONS: The association of the effect on post-prandial metabolism, plasma TNFalpha level and HL activity during prolonged enoxaparin treatment may support the hypothesis that the beneficial outcome of enoxaparin may possibly be linked to anti-inflammatory and lipase-potentiating impact.	Enoxaparin	206-216	lipase C, hepatic type	Homo sapiens	98-100
24094602-9	2013	Administration of enoxaparin attenuated thrombin generation.	Enoxaparin	18-28	coagulation factor II, thrombin	Homo sapiens	40-48
24335994-15	2014	CONCLUSION: The pharmacodynamics of a 30-minute IV enoxaparin infusion was found to produce therapeutic 4 hour anti-Factor Xa levels similar to subcutaneous doses.	Enoxaparin	51-61	coagulation factor X	Homo sapiens	116-125
24458050-1	2014	BACKGROUND: Low anti-factor Xa (anti-Xa) concentrations with twice-daily enoxaparin are associated with venous thromboembolism (VTE) in high-risk trauma patients.	Enoxaparin	73-83	coagulation factor X	Homo sapiens	21-30
24094602-13	2013	Tumor mass resection is related with attenuation of thrombin generation, which is inhibited by postoperative thromboprophylaxis with enoxaparin.	Enoxaparin	133-143	coagulation factor II, thrombin	Homo sapiens	52-60
24094602-15	2013	The assessment of thrombin generation during prophylaxis with enoxaparin allows to identify patients with high residual plasma hypercoagulability.	Enoxaparin	62-72	coagulation factor II, thrombin	Homo sapiens	18-26
23519234-7	2013	Adjusted indirect comparison showed that bid enoxaparin was significantly more effective in preventing VTE than enoxaparin once daily (relative risk [RR], 0.71; 95% CI, 0.61-0.83; P &amp;lt; .00001).	Enoxaparin	45-55	BH3 interacting domain death agonist	Homo sapiens	41-44
23519234-8	2013	For major and clinically relevant hemorrhage, adjusted indirect comparison showed that enoxaparin bid was nonsignificantly associated with increased risk of bleeding (RR 1.27; 95% CI, 0.97-1.65; P = .08) above that of enoxaparin once daily.	Enoxaparin	87-97	BH3 interacting domain death agonist	Homo sapiens	98-101
23519234-8	2013	For major and clinically relevant hemorrhage, adjusted indirect comparison showed that enoxaparin bid was nonsignificantly associated with increased risk of bleeding (RR 1.27; 95% CI, 0.97-1.65; P = .08) above that of enoxaparin once daily.	Enoxaparin	218-228	BH3 interacting domain death agonist	Homo sapiens	98-101
23808469-4	2013	OBJECTIVE: To determine whether the direct thrombin inhibitors lepirudin and argatroban and the predominantly factor Xa inhibitors enoxaparin, danaparoid, and fondaparinux could interfere with LA screening based on dPT.	Enoxaparin	131-141	coagulation factor X	Homo sapiens	110-119
23808469-11	2013	Although heparinase could almost completely neutralize the anti-Xa effect of all investigated factor Xa inhibitors, dPT ratio returned to the basal level only in case of enoxaparin.	Enoxaparin	170-180	Diptericin A	Drosophila melanogaster	116-119
23808469-14	2013	However, dPT seems to be a reliable test for LA screening under enoxaparin therapy after neutralization by heparinase.	Enoxaparin	64-74	Diptericin A	Drosophila melanogaster	9-12
23590781-6	2013	Conversely, enoxaparin use significantly caused the elevation of alanine aminotransferase (one of the liver enzymes) at a higher rate than fondaparinux (30.1% vs 8.3%, respectively; P&lt;.0001).	Enoxaparin	12-22	glutamic--pyruvic transaminase	Homo sapiens	65-89
23673387-0	2013	Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.	Enoxaparin	115-125	serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1	Mus musculus	10-22
27121789-6	2013	The results showed that rivaroxaban (10 mg) and enoxaparin (40 mg) had a similar and rapid onset of action, as indicated by the similar anti-factor Xa activity-time curves, suggesting that both drugs have a similar duration of pharmacological activity at the factor X site.	Enoxaparin	48-58	coagulation factor X	Homo sapiens	141-150
23590781-7	2013	However, the increased alanine aminotransferase levels were transient, and no patient exhibited symptoms of abnormal liver function, such as jaundice or cutaneous pruritus.Fondaparinux and enoxaparin were both effective in preventing venous thromboembolism in Japanese patients undergoing elective TKA.	Enoxaparin	189-199	glutamic--pyruvic transaminase	Homo sapiens	23-47
23200896-5	2013	Melagatran, heparin, and enoxaparin all inhibited thrombin-induced platelet aggregation at clinically relevant concentrations.	Enoxaparin	25-35	coagulation factor II	Rattus norvegicus	50-58
23907946-2	2013	We studied the effects of unfractionated heparin (UFH) vs. enoxaparin vs. sulodexide on the levels and gene expression of osteoprotegerin (OPG), Receptor Activator of Nuclear Factor kB Ligand (RANKL) and von Willebrand factor (vWF) in Human Umbilical Vein Endothelial Cells (HUVEC) culture.	Enoxaparin	59-69	TNF receptor superfamily member 11b	Homo sapiens	122-137
23959669-2	2013	We aimed to compare the effect of unfractionated heparin (UFH) and enoxaparin used as anticoagulants during hemodialysis (HD) on circulating levels of heparin-binding, anti-angiogenic Endostatin, pro-inflammatory RANTES (Regulated upon Activation, Normal T cell Expressed and Secreted), and MCP-1 (Monocyte Chemoattractant Protein-1).	Enoxaparin	67-77	collagen type XVIII alpha 1 chain	Homo sapiens	184-194
23959669-9	2013	Patients with ischemic heart disease had less RANTES increase after 180 min of HD especially during enoxaparin treatment.	Enoxaparin	100-110	C-C motif chemokine ligand 5	Homo sapiens	46-52
23959669-10	2013	CONCLUSION: RANTES is dose-depended and transitory increased in response to both UFH and enoxaparin administration during HD.	Enoxaparin	89-99	C-C motif chemokine ligand 5	Homo sapiens	12-18
23907946-8	2013	A negative correlation between the OPG and sRANKL concentration was noticed in supernatant HUVEC which were incubated with enoxaparine.	Enoxaparin	123-134	TNF receptor superfamily member 11b	Homo sapiens	35-38
23227470-4	2012	WHAT THIS STUDY ADDS: The standard dose of 40 mg enoxaparin led to a significant increase in anti-FXa levels in this selected cohort of ICU patients with normal renal function.	Enoxaparin	49-59	coagulation factor X	Homo sapiens	98-101
23533746-4	2013	Rivaroxaban is one of the new oral anticoagulants and is a direct factor Xa inhibitor that has demonstrated superior efficacy to that of enoxaparin.	Enoxaparin	137-147	coagulation factor X	Homo sapiens	66-75
23227470-10	2012	AIM: In critically ill patients, reduced anti-FXa plasma activity following subcutaneous administration of enoxaparin or nadroparin has been described.	Enoxaparin	107-117	coagulation factor X	Homo sapiens	46-49
23227470-16	2012	RESULTS: The anti-FXa plasma activity increased significantly after enoxaparin administration, with peak levels at 3 h after treatment, but was comparable between the ICU and medical ward groups (median 0.16 IU ml-1 [IQR 0-0.22 IU ml-1] vs. 0.2 IU ml-1 [IQR 0.15-0.27 IU ml-1],respectively, P = 0.13).	Enoxaparin	68-78	coagulation factor X	Homo sapiens	18-21
22876779-12	2012	For major bleeding during the prolonged treatment period, the RR was 2.69 (95% CI 1.65, 4.39) for patients treated with an FXa inhibitor compared with enoxaparin/placebo.	Enoxaparin	151-161	coagulation factor X	Homo sapiens	123-126
22876779-14	2012	CONCLUSION: In acute medically ill patients, prolonged thromboprophylaxis with an oral FXa inhibitor is more protective than regular short-term treatment with enoxaparin.	Enoxaparin	159-169	coagulation factor X	Homo sapiens	87-90
22876779-15	2012	However, treatment with FXa inhibitors is significantly associated with major bleeding, both in long- and short-term treatment compared with enoxaparin.	Enoxaparin	141-151	coagulation factor X	Homo sapiens	24-27
22824193-5	2012	Patients who underwent therapeutic anticoagulation with a heparin infusion or enoxaparin (1 mg/kg BID) were evaluated for neurologic deterioration or hemorrhage extension by CT scan.	Enoxaparin	78-88	BH3 interacting domain death agonist	Homo sapiens	98-101
22345487-2	2012	Two enoxaparin regimens are approved for thromboprophylaxis, one in the United States (30 mg twice daily [bid]) and another in the rest of the world (40 mg once daily [qd]).	Enoxaparin	4-14	BH3 interacting domain death agonist	Homo sapiens	106-109
22565589-0	2012	Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity.	Enoxaparin	32-42	coagulation factor X	Homo sapiens	82-91
22565589-2	2012	We prospectively compared three enoxaparin dosing regimens for the achievement of goal peak anti-Factor Xa levels in medically ill patients (n 5 31) with extreme obesity (body mass index (BMI)   40 kg/m2).	Enoxaparin	32-42	coagulation factor X	Homo sapiens	97-106
22565589-9	2012	To our knowledge this is the first prospective comparative study demonstrating that in extremely obese, medically ill patients enoxaparin 0.5 mg/kg QDay is superior to FD and LD enoxaparin for the achievement of target anti-Factor Xa levels.	Enoxaparin	127-137	coagulation factor X	Homo sapiens	224-233
22088204-5	2012	INTERVENTION(S): The effects of LMWHs (tinzaparin and enoxaparin) on decidual HB-EGF expression and secretion were investigated by Western blot analysis and ELISA, respectively.	Enoxaparin	54-64	heparin binding EGF like growth factor	Homo sapiens	78-84
22038446-3	2012	The aim of this study was therefore to analyse alterations in the expression of M-CSF, VEGF and TGF-ss1 after treatment with enoxaparin in patients with long bone fracture to investigate the effect of LMWH on human fracture healing.	Enoxaparin	125-135	colony stimulating factor 1	Homo sapiens	80-85
22038446-7	2012	RESULTS: M-CSF serum concentrations were found to be significantly higher only at 48 weeks after surgery in enoxaparin.	Enoxaparin	108-118	colony stimulating factor 1	Homo sapiens	9-14
22038446-8	2012	Mean overall VEGF serum concentration was higher in patients with enoxaparin.	Enoxaparin	66-76	vascular endothelial growth factor A	Homo sapiens	13-17
22038446-9	2012	TGF-beta1 serum concentrations were higher at 48 weeks after surgery in patients with enoxaparin.	Enoxaparin	86-96	transforming growth factor beta 1	Homo sapiens	0-9
22038446-10	2012	CONCLUSION: This is the first comparative systemic measurement of M-CSF, VEGF and TGF-ss1 serum levels in patients with and without enoxaparin after long bone fracture.	Enoxaparin	132-142	colony stimulating factor 1	Homo sapiens	66-71
22038446-11	2012	Significant differences of the expression of the growth factors after enoxaparin therapy were only observed at week 48 after surgery for M-CSF and TGF-ss1.	Enoxaparin	70-80	colony stimulating factor 1	Homo sapiens	137-142
22429800-10	2012	In SAVE-HIP1, clinically relevant bleeding and major bleeding were significantly lower in the semuloparin vs. the enoxaparin group.	Enoxaparin	114-124	huntingtin interacting protein 1	Homo sapiens	8-12
21080209-4	2012	Experimental results revealed that LMWH (Enoxaparin, 3500-5500 Da) inhibited the CXCL12-stimulated proliferation, adhesion and colony formation of human colon cancer HCT-116 cells that highly expressed CXCR4.	Enoxaparin	41-51	C-X-C motif chemokine ligand 12	Homo sapiens	81-87
21080209-4	2012	Experimental results revealed that LMWH (Enoxaparin, 3500-5500 Da) inhibited the CXCL12-stimulated proliferation, adhesion and colony formation of human colon cancer HCT-116 cells that highly expressed CXCR4.	Enoxaparin	41-51	C-X-C motif chemokine receptor 4	Homo sapiens	202-207
21905823-10	2011	In conclusion, enoxaparin displayed a direct dose and exposure duration dependent suppressor effect on A549 cell proliferation and the expression of both c-Myc and CD44 in vitro, suggesting reduced proliferative and metastatic potentials of these cells.	Enoxaparin	15-25	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	154-159
22048231-5	2011	The direct inhibitors of FXa, the activated form of factor X--also known as prothrombinase--were found to have a significantly higher TI than that of any other class of anticoagulants, including enoxaparin, suggesting that this mechanism of action provides the best safety-to-efficacy margin.	Enoxaparin	195-205	coagulation factor X	Homo sapiens	25-28
22048231-5	2011	The direct inhibitors of FXa, the activated form of factor X--also known as prothrombinase--were found to have a significantly higher TI than that of any other class of anticoagulants, including enoxaparin, suggesting that this mechanism of action provides the best safety-to-efficacy margin.	Enoxaparin	195-205	coagulation factor X	Homo sapiens	76-90
21871519-13	2011	Enoxaparin significantly decreased the hippocampal TBARS and oxidized protein levels, COX-2 overexpression and reactive gliosis, but it did not influence the SOD and GSH-Px activities, pro-IL-1beta and active caspase-3 overexpressions as well as neurodegeneration following TBI.	Enoxaparin	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	86-91
21871519-13	2011	Enoxaparin significantly decreased the hippocampal TBARS and oxidized protein levels, COX-2 overexpression and reactive gliosis, but it did not influence the SOD and GSH-Px activities, pro-IL-1beta and active caspase-3 overexpressions as well as neurodegeneration following TBI.	Enoxaparin	0-10	caspase 3	Rattus norvegicus	209-218
21409381-0	2011	Non-therapeutic anti-FXa levels are common among medical ward patients treated with enoxaparin.	Enoxaparin	84-94	coagulation factor X	Homo sapiens	21-24
21910821-6	2011	The primary composite endpoint assessed the clinical performance of enoxaparin by comparing the peri-interventional rate of thromboembolia/occlusion (efficacy) of endovascularly reconstructed areas, of bleeding according to the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) criteria (safety) and of any necessary re-intervention for any percutaneous transluminal angioplasty (PTA)-related bleeding.	Enoxaparin	68-78	plasminogen activator, tissue type	Homo sapiens	268-272
20682597-6	2011	Interestingly, TFPI increment at T10 was the highest, dose-dependent, and accompanied by PF 1 + 2 decrease under enoxaparin administration.	Enoxaparin	113-123	tissue factor pathway inhibitor	Homo sapiens	15-19
20682597-8	2011	Only short-term, overdialytic differences were noticed, indicating a single bolus of enoxaparin (0.75 mg/kg) as the most potent stimulus for endothelial TFPI.	Enoxaparin	85-95	tissue factor pathway inhibitor	Homo sapiens	153-157
22040919-9	2011	In contrast, prothrombinase- and clot-induced prothrombin activation were resistant to inhibition by enoxaparin.	Enoxaparin	101-111	coagulation factor X	Homo sapiens	13-28
22345625-3	2011	We asked whether levels of antibody to heparin-platelet factor 4 (PF4) complex were differentially present in unfractionated heparin (UFH) versus Enoxaparin, following hip fracture and whether one particular subtype of antibodies was more prevalent.	Enoxaparin	146-156	platelet factor 4	Homo sapiens	39-64
22345625-3	2011	We asked whether levels of antibody to heparin-platelet factor 4 (PF4) complex were differentially present in unfractionated heparin (UFH) versus Enoxaparin, following hip fracture and whether one particular subtype of antibodies was more prevalent.	Enoxaparin	146-156	platelet factor 4	Homo sapiens	66-69
21905823-10	2011	In conclusion, enoxaparin displayed a direct dose and exposure duration dependent suppressor effect on A549 cell proliferation and the expression of both c-Myc and CD44 in vitro, suggesting reduced proliferative and metastatic potentials of these cells.	Enoxaparin	15-25	CD44 molecule (Indian blood group)	Homo sapiens	164-168
21584633-0	2011	Reduced thrombin generation and soluble P-selectin after intravenous enoxaparin during PCI.	Enoxaparin	69-79	selectin P	Homo sapiens	40-50
20825842-9	2011	From the 28 patients enrolled, 75% (group 1, n = 21) received at least 0.9 mg/kg per dose BID and 25% (group 2, n = 7) received less than 0.9 mg/kg per dose BID of enoxaparin.	Enoxaparin	164-174	BH3 interacting domain death agonist	Homo sapiens	157-160
21726460-3	2011	We hypothesized that subcutaneous injections of enoxaparin would decrease the effects of hyperoxia on high-tidal-volume ventilation-induced HMGB1 production and neutrophil infiltration via the serine/threonine kinase/protein kinase B (Akt) pathway.	Enoxaparin	48-58	high mobility group box 1	Mus musculus	140-145
21726460-3	2011	We hypothesized that subcutaneous injections of enoxaparin would decrease the effects of hyperoxia on high-tidal-volume ventilation-induced HMGB1 production and neutrophil infiltration via the serine/threonine kinase/protein kinase B (Akt) pathway.	Enoxaparin	48-58	thymoma viral proto-oncogene 1	Mus musculus	235-238
21726460-9	2011	Hyperoxia-induced augmentation of ventilator-induced lung injury was attenuated with Akt deficient mice and pharmacological inhibition of Akt activity by enoxaparin.	Enoxaparin	154-164	thymoma viral proto-oncogene 1	Mus musculus	138-141
21726460-10	2011	CONCLUSION: These data suggest that enoxaparin attenuates hyperoxia-augmented high-tidal-volume ventilation-induced neutrophil influx and HMGB1 production through inhibition of the Akt pathway.	Enoxaparin	36-46	high mobility group box 1	Mus musculus	138-143
21726460-10	2011	CONCLUSION: These data suggest that enoxaparin attenuates hyperoxia-augmented high-tidal-volume ventilation-induced neutrophil influx and HMGB1 production through inhibition of the Akt pathway.	Enoxaparin	36-46	thymoma viral proto-oncogene 1	Mus musculus	181-184
21726460-11	2011	Understanding the protective mechanism of enoxaparin related with the reduction of HMGB1 may help further knowledge of the effects of mechanical forces in the lung and development of possible therapeutic strategies involved in acute lung injury.	Enoxaparin	42-52	high mobility group box 1	Mus musculus	83-88
20645940-7	2011	CONCLUSION: Vitamin E and enoxaparin are able not only to prevent foetal wastage but also to balance IL-6 and VEGF placental levels, presenting a new potential therapeutic alternative for patients with recurrent abortion not associated with thrombophilias.	Enoxaparin	26-36	interleukin 6	Homo sapiens	101-105
21526168-2	2011	Its mechanism of action is antithrombin independent and differs from that of other anticoagulants, such as warfarin (a vitamin K antagonist), enoxaparin (an indirect thrombin/Factor Xa inhibitor) and dabigatran (a direct thrombin inhibitor).	Enoxaparin	142-152	coagulation factor X	Homo sapiens	175-184
21526168-2	2011	Its mechanism of action is antithrombin independent and differs from that of other anticoagulants, such as warfarin (a vitamin K antagonist), enoxaparin (an indirect thrombin/Factor Xa inhibitor) and dabigatran (a direct thrombin inhibitor).	Enoxaparin	142-152	coagulation factor II, thrombin	Homo sapiens	166-174
20645940-7	2011	CONCLUSION: Vitamin E and enoxaparin are able not only to prevent foetal wastage but also to balance IL-6 and VEGF placental levels, presenting a new potential therapeutic alternative for patients with recurrent abortion not associated with thrombophilias.	Enoxaparin	26-36	vascular endothelial growth factor A	Homo sapiens	110-114
20972772-3	2011	In this study, a fluorogenic anti-FXa assay was developed using a commercially available fluorogenic substrate with an attached 6-amino-1-naphthalene-sulfonamide (ANSN) fluorophore and was used for the determination of two LMWHs, enoxaparin and tinzaparin and the heparinoid, danaparoid.	Enoxaparin	230-240	coagulation factor X	Homo sapiens	34-37
21083516-0	2011	Effects of enoxaparin preparations on thrombin generation and their correlation with their anti-FXa activity.	Enoxaparin	11-21	coagulation factor II, thrombin	Homo sapiens	38-46
21083516-0	2011	Effects of enoxaparin preparations on thrombin generation and their correlation with their anti-FXa activity.	Enoxaparin	11-21	coagulation factor X	Homo sapiens	96-99
20807891-7	2010	Coadministration of FXI ASO with enoxaparin or the antiplatelet drug clopidogrel produced improved antithrombotic activity without increased bleeding.	Enoxaparin	33-43	coagulation factor XI	Mus musculus	20-23
21150227-2	2011	OBJECTIVE: To evaluate the anticoagulant effects of the two LMWHs nadroparin and enoxaparin on endogenous formation of FXa or FIIa in cord versus adult platelet-poor plasma (PPP) and on thrombelastometry profiles in cord versus adult whole blood (WB).	Enoxaparin	81-91	coagulation factor X	Homo sapiens	119-122
21150227-4	2011	METHODS: The effects of nadroparin, enoxaparin, or UH on endogenous formation of FXa or FIIa was investigated in tissue factor-activated PPP using a subsampling technique and chromogenic substrates.	Enoxaparin	36-46	coagulation factor X	Homo sapiens	81-84
21150227-6	2011	RESULTS: The major findings are (i) nadroparin is as efficient as enoxaparin concerning inhibition of the endogenous formation of FXa and FIIa, (ii) cord PPP and WB are significantly more susceptible to the addition of LMWHs or UH than adult PPP or WB, and (iii) compared by equivalent anti-FXa activity, the anticoagulant action of UH is markedly higher than that of the LMWHs in PPP and WB of neonatal or adult origin.	Enoxaparin	66-76	coagulation factor X	Homo sapiens	130-133
21175312-2	2010	Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some degree.	Enoxaparin	38-48	coagulation factor X	Homo sapiens	71-80
21175312-2	2010	Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some degree.	Enoxaparin	38-48	coagulation factor II, thrombin	Homo sapiens	98-106
20870944-8	2010	Furthermore, FXa-induced cleavage of C3 was significantly suppressed in the presence of the selective FXa inhibitors fondaparinux and enoxaparin in a concentration-dependent manner.	Enoxaparin	134-144	coagulation factor X	Homo sapiens	13-16
19850587-0	2010	FXa inhibition and coagulation changes during DVT prophylaxis by enoxaparin over the course of a 15-day follow-up in septic patients.	Enoxaparin	65-75	coagulation factor X	Homo sapiens	0-3
21057164-2	2010	The present study investigated the effect of low molecular weight heparin (Enoxaparin) on carbon tetrachloride (CCl4) induced hepatic necrosis and apoptosis in rats.	Enoxaparin	75-85	C-C motif chemokine ligand 4	Rattus norvegicus	112-116
20870944-8	2010	Furthermore, FXa-induced cleavage of C3 was significantly suppressed in the presence of the selective FXa inhibitors fondaparinux and enoxaparin in a concentration-dependent manner.	Enoxaparin	134-144	coagulation factor X	Homo sapiens	102-105
21057164-13	2010	CONCLUSION: Enoxaparin have beneficial effects against necrosis as well as apoptosis at the early stage of CCL4 induced liver injury.	Enoxaparin	12-22	C-C motif chemokine ligand 4	Rattus norvegicus	107-111
20600909-0	2010	Enoxaparin treatment administered at both early and late stages of amyloid beta deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Abeta levels.	Enoxaparin	0-10	amyloid beta (A4) precursor protein	Mus musculus	167-172
20600909-1	2010	Enoxaparin (Enox), a low molecular weight heparin, has been shown to lower brain amyloid beta (A beta) load in a mouse model for Alzheimer"s disease.	Enoxaparin	0-10	amyloid beta (A4) precursor protein	Mus musculus	95-101
20600909-1	2010	Enoxaparin (Enox), a low molecular weight heparin, has been shown to lower brain amyloid beta (A beta) load in a mouse model for Alzheimer"s disease.	Enoxaparin	0-4	amyloid beta (A4) precursor protein	Mus musculus	95-101
20546854-0	2010	Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment.	Enoxaparin	26-36	asparaginase and isoaspartyl peptidase 1	Homo sapiens	118-132
20505748-6	2010	We also show that two clinically approved LMWHs, tinzaparin and enoxaparin, are effective inhibitors of thrombin generation and thrombin activity in plasma.	Enoxaparin	64-74	coagulation factor II, thrombin	Homo sapiens	104-112
20505748-6	2010	We also show that two clinically approved LMWHs, tinzaparin and enoxaparin, are effective inhibitors of thrombin generation and thrombin activity in plasma.	Enoxaparin	64-74	coagulation factor II, thrombin	Homo sapiens	128-136
20339086-8	2010	As secondary objective we investigated the use of enoxaparin for VTE prophylaxis in the HRG.	Enoxaparin	50-60	histidine rich glycoprotein	Homo sapiens	88-91
20441964-2	2010	A fluorogenic anti-factor Xa (anti-FXa) assay has been developed for the determination of unfractionated heparin (UFH), low molecular weight heparins (LMWHs), namely enoxaparin and tinzaparin, and the synthetic heparinoid danaparoid, in commercial human pooled plasma.	Enoxaparin	166-176	coagulation factor X	Homo sapiens	35-38
19962723-5	2010	Vein re-opening was significantly higher on P-selectin/ PSGL-1 compounds, when compared to saline (Inverse Variance [IV] 95% CI; 44.37 [17.77-70.96], p=0.001, I(2)=97%) and similar to enoxaparin (IV 95% CI; 5.03 [-8.88-18.95], p=0.48, I(2)=41%).	Enoxaparin	184-194	selectin P	Homo sapiens	44-54
19829297-1	2010	OBJECTIVE: The objective of the study was to evaluate anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy.	Enoxaparin	93-103	coagulation factor X	Homo sapiens	59-68
19049846-6	2010	The extent of enoxaparin-induced MPO release and the improvement in endothelial function showed a good correlation (r=0.67, p&lt;0.001).	Enoxaparin	14-24	myeloperoxidase	Homo sapiens	33-36
19517216-1	2010	Owing to its beneficial pharmacological profile, the low-molecular-weight heparin (LMWH) enoxaparin is increasingly being taken as an alternative to UFH in the treatment of ACS with an early invasive strategy and in elective percutaneous coronary interventions (PCI).	Enoxaparin	89-99	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	173-176
19517216-3	2010	The aim of the present study was to test in vitro the hypotheses that (i) inhibiting thrombin or thrombin generation by administering LMWH is a critical intervention in preventing catheter thrombus formation and (ii) other LMWH such as certoparin or dalteparin are as effective as enoxaparin.	Enoxaparin	281-291	coagulation factor II, thrombin	Homo sapiens	85-93
20050998-7	2010	RESULTS: Anti-PF4/heparin immunization was more frequent after knee vs. hip surgery (particularly for enoxaparin), and when enoxaparin was given post- rather than pre-elective surgery; however, the opposite occurred with hip fracture surgery, that is, antibody formation was more frequent when enoxaparin or fondaparinux was given presurgery.	Enoxaparin	102-112	platelet factor 4	Homo sapiens	14-17
20050998-7	2010	RESULTS: Anti-PF4/heparin immunization was more frequent after knee vs. hip surgery (particularly for enoxaparin), and when enoxaparin was given post- rather than pre-elective surgery; however, the opposite occurred with hip fracture surgery, that is, antibody formation was more frequent when enoxaparin or fondaparinux was given presurgery.	Enoxaparin	124-134	platelet factor 4	Homo sapiens	14-17
20050998-7	2010	RESULTS: Anti-PF4/heparin immunization was more frequent after knee vs. hip surgery (particularly for enoxaparin), and when enoxaparin was given post- rather than pre-elective surgery; however, the opposite occurred with hip fracture surgery, that is, antibody formation was more frequent when enoxaparin or fondaparinux was given presurgery.	Enoxaparin	124-134	platelet factor 4	Homo sapiens	14-17
20039931-7	2010	CD40 ligand expression on platelets was significantly reduced following PCI with HD-tirofiban and either UFH or enoxaparin.	Enoxaparin	112-122	CD40 molecule	Homo sapiens	0-4
20039931-9	2010	Prothrombin fragment 1+2, D-dimer, von Willebrand factor and high sensitive C-reactive protein levels were significantly less post PCI in the enoxaparin group compared with those patients receiving UFH.	Enoxaparin	142-152	C-reactive protein	Homo sapiens	76-94
20008145-7	2010	Treatment from days 7 through 14 with enoxaparin, a functional analogue of the Sdc1 heparan sulfate chains, significantly reduced lethality of KO mice due to DSS-induced colitis, which was correlated with improved mucosal healing.	Enoxaparin	38-48	syndecan 1	Mus musculus	79-83
19954711-10	2009	Enoxaparin induced a higher release of total TFPI, but not on free TFPI, and a longer prolongation of APTT and TT (Emax) than bemiparin, with no differences between groups on Tp-TmT.	Enoxaparin	0-10	tissue factor pathway inhibitor	Homo sapiens	45-49
25949368-0	2009	Enoxaparin decreases serum MCP-1 concentration during haemodialysis-preliminary report.	Enoxaparin	0-10	C-C motif chemokine ligand 2	Homo sapiens	27-32
19625075-3	2009	Although the dose in cohort 1 and 2 was similar (median 7000 IE BID), a-FXa-activity was significantly larger under enoxaparin than under tinzaparin (e.g. median at V2: 0.70 IU/ml vs. 0.33 IU/ml).	Enoxaparin	116-126	coagulation factor X	Homo sapiens	72-75
19625075-4	2009	Also, prophylactic enoxaparin exhibited larger a-FXa-activity than tinzaparin (e.g. median at V2: 0.37 IU/ml vs. 0.22 IU/ml).	Enoxaparin	19-29	coagulation factor X	Homo sapiens	49-52
19625075-9	2009	Minimal bleeding events occurred in 6 patients (2 under tinzaparin, 4 under enoxaparin) and were associated with significantly higher anti-FXa-activity.	Enoxaparin	76-86	coagulation factor X	Homo sapiens	139-142
19625075-10	2009	In conclusion, although marked differences between tinzaparin and enoxaparin based on anti-FXa-activity were seen, markers of in vivo biological activity such as TFPI and D-dimer were not different.	Enoxaparin	66-76	coagulation factor X	Homo sapiens	91-94
19703818-5	2009	In addition, sulodexide had a stronger inhibitory effect on TF-mediated microparticle generation (IC(50) = 2.8 microg/ mL), P-selectin expression (IC(50) = 4.8 microg/ml), and platelet aggregate formation (IC(50) = 8.5 microg/mL) compared to higher IC(50) values with enoxaparin.	Enoxaparin	268-278	coagulation factor III, tissue factor	Homo sapiens	60-62
19373478-0	2009	Cerebral venous thrombosis treated with enoxaparin in an IUGR neonate with DIC.	Enoxaparin	40-50	solute carrier family 25 member 10	Homo sapiens	75-78
19930848-6	2009	It is concluded that enoxaparin resistance, resulting in high levels of factor Xa residual activity, should be considered in patients with recurrent ischaemia.	Enoxaparin	21-31	coagulation factor X	Homo sapiens	72-81
19628124-2	2009	BACKGROUND: The OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial showed that fondaparinux reduced major bleeding by 50% compared with enoxaparin while preserving similar efficacy.	Enoxaparin	163-173	cAMP responsive element binding protein 3 like 1	Homo sapiens	16-21
19628124-8	2009	There was a 40% reduction in major bleeding with fondaparinux compared with enoxaparin in those treated with GP IIb/IIIa (5.2% vs. 8.3%, hazard ratio [HR]: 0.61, p &lt; 0.001).	Enoxaparin	76-86	integrin subunit alpha 2b	Homo sapiens	109-115
19038418-0	2009	Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.	Enoxaparin	88-98	insulin	Homo sapiens	14-21
19038418-8	2009	Enoxaparin may be administered in whole milligram doses via insulin syringe, where one milligram of enoxaparin equals one unit on the 100 unit graduated insulin syringe.	Enoxaparin	0-10	insulin	Homo sapiens	60-67
19038418-11	2009	OUTCOME: to determine the occurrence rate of supra-therapeutic anticoagulation as indicated by anti-Xa levels &gt;1.0 u/ml, when enoxaparin doses are rounded up to the whole milligram, and are administered using insulin syringes.	Enoxaparin	129-139	insulin	Homo sapiens	212-219
19038418-18	2009	CONCLUSION: Whole milligram enoxaparin dosing administered via an insulin syringe safely and effectively, achieved therapeutic levels in infants and children.	Enoxaparin	28-38	insulin	Homo sapiens	66-73
19038418-19	2009	The reduced incidence of enoxaparin dosing errors suggests that whole milligram enoxaparin dosing via an insulin syringe is a method that should be considered for standard of care.	Enoxaparin	80-90	insulin	Homo sapiens	105-112
19102516-7	2009	Therapeutic anti-factor Xa was observed in 85.3% of patients treated with enoxaparin sodium 0.61-0.8 mg/kg/12h, and in 82.6% of patients treated with enoxaparin sodium 0.81-1.1 mg/kg/12h.	Enoxaparin	74-91	coagulation factor X	Homo sapiens	17-26
17895513-8	2009	During enoxaparin-anticoagulated HD, only plasma PAI-1 levels decreased by 32% after 180 minutes compared with the baseline values.	Enoxaparin	7-17	serpin family E member 1	Homo sapiens	49-54
17895513-10	2009	CONCLUSION: Enoxaparin-anticoagulated HD is related to transient plasma PAI-1 decrease, whereas UFH anticoagulation may be the cause of delayed PAI-1 and TM depletion, which is an untoward consequence of enhanced coagulation activity in chronic HD patients.	Enoxaparin	12-22	serpin family E member 1	Homo sapiens	72-77
18234290-2	2009	We aimed to investigate the effect of UFH and enoxaparin on plasma levels of prothrombin fragment 1+2 (PF 1+2) and thrombin/antithrombin complex (TAT) as markers of intravascular thrombogenesis during HD.	Enoxaparin	46-56	PHD finger protein 12	Homo sapiens	103-107
18234290-2	2009	We aimed to investigate the effect of UFH and enoxaparin on plasma levels of prothrombin fragment 1+2 (PF 1+2) and thrombin/antithrombin complex (TAT) as markers of intravascular thrombogenesis during HD.	Enoxaparin	46-56	coagulation factor II, thrombin	Homo sapiens	80-88
18234290-6	2009	PF 1+2 significantly decreased during both UFH (chi(2) ANOVA=9.82, P=0.007) and enoxaparin (chi(2) ANOVA=29.40, P&lt;10(-6)) anticoagulated HD, while over-HD TAT levels changes differed depending on the type of heparin.	Enoxaparin	80-90	PHD finger protein 12	Homo sapiens	0-4
18234290-7	2009	The switch from enoxaparin to UFH treatment was connected with a significantly higher PF 1+2 after 10 and 180 min as well as higher TAT concentration after 180 min of HD.	Enoxaparin	16-26	PHD finger protein 12	Homo sapiens	86-101
18234290-8	2009	Only during enoxaparin anticoagulated HD 34% PF 1+2 decrease and TAT levels after 180 min of HD was closely associated with heparin dosage.	Enoxaparin	12-22	PHD finger protein 12	Homo sapiens	45-49
20339323-3	2009	The effects of increasing amounts of nadroparin, enoxaparin, or unfractionated heparin on the time-course of FXa or FIIa formation were investigated in tissue factor activated platelet-poor plasma using a subsampling technique and chromogenic substrates.	Enoxaparin	49-59	coagulation factor X	Homo sapiens	109-112
20339323-5	2009	Nadroparin is as efficient as enoxaparin concerning suppression of endogenous FXa or FIIa formation.	Enoxaparin	30-40	coagulation factor X	Homo sapiens	78-81
19580651-3	2009	We hypothesized that subcutaneous injections of unfractionated heparin and enoxaparin would decrease neutrophil infiltration, lung edema, and plasminogen-activator inhibitor-1 (PAI-1) production in mice exposed to high-tidal-volume ventilation.	Enoxaparin	75-85	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	142-175
19580651-3	2009	We hypothesized that subcutaneous injections of unfractionated heparin and enoxaparin would decrease neutrophil infiltration, lung edema, and plasminogen-activator inhibitor-1 (PAI-1) production in mice exposed to high-tidal-volume ventilation.	Enoxaparin	75-85	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	177-182
19580651-12	2009	Understanding the protective mechanism of unfractionated heparin and enoxaparin related to the reduction of PAI-1 may afford further knowledge of the effects of mechanical forces in the lung and development of possible therapeutic strategies involved in acute lung injury.	Enoxaparin	69-79	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	108-113
19124079-6	2009	Lepirudin most efficiently delayed the lag time whereas enoxaparin was the most powerfully drug for diminishing the endogenous thrombin potential (ETP).	Enoxaparin	56-66	coagulation factor II, thrombin	Homo sapiens	127-135
19102516-7	2009	Therapeutic anti-factor Xa was observed in 85.3% of patients treated with enoxaparin sodium 0.61-0.8 mg/kg/12h, and in 82.6% of patients treated with enoxaparin sodium 0.81-1.1 mg/kg/12h.	Enoxaparin	150-167	coagulation factor X	Homo sapiens	17-26
18838932-3	2008	However, little pharmacodynamic data are available for determining the appropriate dosing and monitoring (by anti-Factor Xa levels) of intravenous enoxaparin.	Enoxaparin	147-157	coagulation factor X	Homo sapiens	114-123
22477550-1	2009	AIM: To assess whether there was an increased risk of bleeding with enoxaparin in patients with a creatinine clearance (CCT) of less than 30 mL/min.	Enoxaparin	68-78	CCT	Homo sapiens	120-123
22477550-15	2009	CONCLUSION: It is safe to administer enoxaparin once a day to patients with renal impairment and a CCT of less than 30 mL/min.	Enoxaparin	37-47	CCT	Homo sapiens	99-102
19343162-2	2008	AIM: To compare the inhibition of coagulation factor Xa by enoxaparin and nadroparin in the therapy of ACS.	Enoxaparin	59-69	acyl-CoA synthetase long chain family member 3	Homo sapiens	103-106
18940719-4	2008	We demonstrate that both heparin and its low-molecular-weight derivative enoxaparin (0.5-50 u/mL) inhibited PS(+ve)-RBC adhesion to immobilized TSP in a concentration-dependent manner (21% to 77% inhibition, P &lt; 0.05).	Enoxaparin	73-83	thrombospondin 1	Homo sapiens	144-147
18940719-10	2008	Our results demonstrate that PS-positive erythrocytes bind to both immobilized and soluble TSP via its heparin-binding domain and that both heparin and enoxaparin, at clinically relevant concentrations, block this interaction.	Enoxaparin	152-162	thrombospondin 1	Homo sapiens	91-94
18308578-9	2008	Both aspirin and enoxaparin normalized brain concentrations of PGE and TNF-alpha and elevated thrombin inhibitors, the latter effect being more pronounced for enoxaparin.	Enoxaparin	17-27	tumor necrosis factor	Mus musculus	71-80
18308578-9	2008	Both aspirin and enoxaparin normalized brain concentrations of PGE and TNF-alpha and elevated thrombin inhibitors, the latter effect being more pronounced for enoxaparin.	Enoxaparin	17-27	coagulation factor II	Mus musculus	94-102
18498878-12	2008	RESULTS: At 24 h reperfusion, there was increased expression of MIP-2, MCP-1, MPO, and TAT III in saline and enoxaparin treated mice compared with control (*P &lt; 0.05).	Enoxaparin	109-119	chemokine (C-X-C motif) ligand 2	Mus musculus	64-69
18498878-12	2008	RESULTS: At 24 h reperfusion, there was increased expression of MIP-2, MCP-1, MPO, and TAT III in saline and enoxaparin treated mice compared with control (*P &lt; 0.05).	Enoxaparin	109-119	chemokine (C-C motif) ligand 2	Mus musculus	71-76
18498878-12	2008	RESULTS: At 24 h reperfusion, there was increased expression of MIP-2, MCP-1, MPO, and TAT III in saline and enoxaparin treated mice compared with control (*P &lt; 0.05).	Enoxaparin	109-119	myeloperoxidase	Mus musculus	78-81
18308578-9	2008	Both aspirin and enoxaparin normalized brain concentrations of PGE and TNF-alpha and elevated thrombin inhibitors, the latter effect being more pronounced for enoxaparin.	Enoxaparin	159-169	coagulation factor II	Mus musculus	94-102
19343162-8	2008	CONCLUSIONS: The results of the present study demonstrate a highly significant difference in anti-Xa activity of enoxaparin and nadroparin in their recommended dosing regimens, in the therapy of ACS 3 h after subcutaneous administration; the anticoagulant effect of enoxaparin was markedly stronger than that of nadroparin.	Enoxaparin	113-123	acyl-CoA synthetase long chain family member 3	Homo sapiens	195-200
17950793-11	2007	In conclusion, for patients with ACS/NSTEMI, reduced-dose enoxaparin combined with dual-antiplatelet therapy followed by triple-antiplatelet therapy alone (without additional anticoagulation) during subsequent PCI appears safe and may prove efficacious.	Enoxaparin	58-68	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	33-36
17692905-8	2008	Similarly, the tube formation induced by standard VEGF, FGF-2, or TNF-alpha was 100% inhibited by enoxaparin, and 70-90% by dalteparin, whereas minor or no inhibition was observed with UFH.	Enoxaparin	98-108	vascular endothelial growth factor A	Homo sapiens	50-54
17692905-8	2008	Similarly, the tube formation induced by standard VEGF, FGF-2, or TNF-alpha was 100% inhibited by enoxaparin, and 70-90% by dalteparin, whereas minor or no inhibition was observed with UFH.	Enoxaparin	98-108	fibroblast growth factor 2	Homo sapiens	56-61
17692905-8	2008	Similarly, the tube formation induced by standard VEGF, FGF-2, or TNF-alpha was 100% inhibited by enoxaparin, and 70-90% by dalteparin, whereas minor or no inhibition was observed with UFH.	Enoxaparin	98-108	tumor necrosis factor	Homo sapiens	66-75
17621651-0	2007	Macroscopic thrombus formation on angioplasty equipment following antithrombin therapy with enoxaparin.	Enoxaparin	92-102	serpin family C member 1	Homo sapiens	66-78
17621651-2	2007	We evaluated the incidence and consequences of periprocedural macroscopic thrombus formation on PCI equipment following antithrombin therapy with enoxaparin.	Enoxaparin	146-156	serpin family C member 1	Homo sapiens	120-132
17621651-3	2007	Between April 2003 and December 2004, all patients undergoing cardiac catheterization following antithrombin therapy with enoxaparin were evaluated.	Enoxaparin	122-132	serpin family C member 1	Homo sapiens	96-108
17621651-11	2007	Percutaneous coronary intervention following antithrombin therapy with enoxaparin is associated with a 5% incidence of macroscopic thrombus formation on PCI equipment.	Enoxaparin	71-81	serpin family C member 1	Homo sapiens	45-57
17525363-6	2007	In an in vitro assay, heparin and to a lesser extent enoxaparin, but not bivalirudin or eptifibatide, stimulated MPO release from and binding to neutrophils and neutrophil activation.	Enoxaparin	53-63	myeloperoxidase	Homo sapiens	113-116
17920287-8	2007	CONCLUSION: The traditional UFH regimen, in contrast to enoxaparin treatment, is connected with dose-depended VEGF(165) decrease during HD procedure.	Enoxaparin	56-66	vascular endothelial growth factor A	Homo sapiens	110-114
17920287-5	2007	VEGF(165) significantly decreased during both enoxaparin (chi(2) ANOVA=33.0, P&lt;10(-6)) and UFH (chi(2) ANOVA=27.2, P&lt;10(-6)) anticoagulated HD, while over-HD bFGF remained stable regardless of the type of heparin.	Enoxaparin	46-56	vascular endothelial growth factor A	Homo sapiens	0-4
17920287-6	2007	The switch from enoxaparin to UFH treatment was connected with 34% VEGF(165) decrease after 180min of HD and had no impact on bFGF.	Enoxaparin	16-26	vascular endothelial growth factor A	Homo sapiens	67-71
17554520-7	2007	Newborns required increased doses of enoxaparin to achieve therapeutic anti-FXa levels (mean 1.62[Symbol: see text]mg/kg per dose) compared with infants aged 2-12 months (mean 1.12 mg/kg per dose; p=0.0002).	Enoxaparin	37-47	coagulation factor X	Homo sapiens	76-79
17600038-8	2007	CONCLUSIONS: When compared with UFH, enoxaparin was associated with superior efficacy as adjunctive antithrombin therapy among &gt;49 000 patients across the ACS spectrum.	Enoxaparin	37-47	serpin family C member 1	Homo sapiens	100-112
17041566-10	2007	Importantly, un-fractionated as well as low molecular weight heparin (enoxaparin), which exhibit a strong inhibitory activity towards heparanase, have proven efficacious in ulcerative colitis and Crohn"s disease patients, suggesting that heparanase is actively involved in these pathologies and thus may be considered as a target for the development of anti-inflammatory therapies.	Enoxaparin	70-80	heparanase	Homo sapiens	134-144
17629851-5	2007	Enoxaparin and nadroparin behave nearly identical in their binding affinity to both P-selectin ( KD 4.60 x 10 (- 6) M versus 7.61 x 10 (- 6) M) and L-selectin ( KD 2.01 x 10 (- 6) M versus 2.84 x 10 (- 6) M).	Enoxaparin	0-10	selectin P	Homo sapiens	84-94
17629851-5	2007	Enoxaparin and nadroparin behave nearly identical in their binding affinity to both P-selectin ( KD 4.60 x 10 (- 6) M versus 7.61 x 10 (- 6) M) and L-selectin ( KD 2.01 x 10 (- 6) M versus 2.84 x 10 (- 6) M).	Enoxaparin	0-10	selectin L	Homo sapiens	148-158
17389624-0	2007	Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-beta 1 during haemodialysis: a cross-over study.	Enoxaparin	0-10	transforming growth factor beta 1	Homo sapiens	85-95
17389624-2	2007	In this cross-over study, we compared the effects of enoxaparin and unfractionated heparin (UFH) used as anticoagulants during haemodialysis (HD) on plasma TGF-beta1 levels and some platelet activation markers: platelet-derived growth factor-AB (PDGF-AB), beta-thromboglobulin (beta-TG) and platelet factor-4 (PF-4).	Enoxaparin	53-63	transforming growth factor beta 1	Homo sapiens	156-165
17389624-6	2007	RESULTS: Pre-dialysis, TGF-beta1 levels tended to be lower in patients anticoagulated with enoxaparin compared with UFH [6.9 (3.3-21.9) ng/ml vs 8.4 (3.8-30.2) ng/ml, respectively; P = 0.05].	Enoxaparin	91-101	transforming growth factor beta 1	Homo sapiens	23-32
17389624-8	2007	The 35% increase in plasma TGF-beta1 after 180 min of HD positively correlated with the enoxaparin dose/kg (r = 0.553, P = 0.008) and, interestingly, negatively with the baseline level of the cytokine (r = -0.544, P = 0.009).	Enoxaparin	88-98	transforming growth factor beta 1	Homo sapiens	27-36
17389624-10	2007	CONCLUSION: Enoxaparin, compared with UFH, induces a rapid overdialytic but not sustained increase in plasma TGF-beta1 levels.	Enoxaparin	12-22	transforming growth factor beta 1	Homo sapiens	109-118
17489664-1	2007	Enoxaparin is a low-molecular-weight heparin (LMWH) derivative that exerts its anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa.	Enoxaparin	0-10	serpin family C member 1	Homo sapiens	110-126
17489664-1	2007	Enoxaparin is a low-molecular-weight heparin (LMWH) derivative that exerts its anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa.	Enoxaparin	0-10	coagulation factor X	Homo sapiens	155-164
17461929-2	2007	OBJECTIVE: We aimed to profile the inhibition of thrombin generation induced by bemiparin, enoxaparin, nadroparin, dalteparin and tinzaparin in platelet-rich plasma (PRP), and to compare them with UFH and fondaparinux (a synthetic pentasaccharide that specifically enhances FXa inhibition).	Enoxaparin	91-101	coagulation factor II, thrombin	Homo sapiens	49-57
17041566-10	2007	Importantly, un-fractionated as well as low molecular weight heparin (enoxaparin), which exhibit a strong inhibitory activity towards heparanase, have proven efficacious in ulcerative colitis and Crohn"s disease patients, suggesting that heparanase is actively involved in these pathologies and thus may be considered as a target for the development of anti-inflammatory therapies.	Enoxaparin	70-80	heparanase	Homo sapiens	238-248
16194212-0	2005	Placental TFPI is decreased in gestational vascular complications and can be restored by maternal enoxaparin treatment.	Enoxaparin	98-108	tissue factor pathway inhibitor	Homo sapiens	10-14
17139378-13	2006	Both NA-LMWH and enoxaparin caused similar TFPI release from endothelial cells in vitro.	Enoxaparin	17-27	tissue factor pathway inhibitor	Mus musculus	43-47
16997938-2	2006	This study was designed to investigate the effects of heparin and LMWHs, enoxaparin and tinzaparin, on E-cadherin and laminin expression in placental and decidual tissues in rat pregnancy.	Enoxaparin	73-83	cadherin 1	Rattus norvegicus	103-113
16997938-5	2006	RESULTS: E-cadherin placental staining score of heparin group was significantly lower and E-cadherin decidual staining score of heparin and enoxaparin groups were significantly lower than control group.	Enoxaparin	140-150	cadherin 1	Rattus norvegicus	90-100
16997938-7	2006	CONCLUSIONS: Heparin and enoxaparin can reduce E-cadherin expression but not laminin expression in rat pregnancy.	Enoxaparin	25-35	cadherin 1	Rattus norvegicus	47-57
16717032-5	2006	In the THRIVE Treatment trial, ALAT was significantly higher at week 2 for enoxaparin/warfarin (p =&gt; .0039, t test) and at months 3 and 6 for ximelagatran (p = .0453, p = .0014, respectively).	Enoxaparin	75-85	glutamic--pyruvic transaminase	Homo sapiens	31-35
16717032-10	2006	The ASAT/ALAT ratios were lower at week 2 for enoxaparin/warfarin (t-test, p = .0032) and at month 3 and 6 for 2 x 36 mg versus warfarin or 2 x 24 mg Ximelagatran (p between .0187 and .0002).	Enoxaparin	46-56	glutamic--pyruvic transaminase	Homo sapiens	9-13
17124098-10	2006	The OASIS 5 trial in non-ST-segment elevation acute coronary syndromes recently demonstrated that the fondaparinux dose approved for prophylaxis of deep venous thrombosis is as efficacious with respect to ischemic outcomes as therapeutic doses of enoxaparin; fondaparinux, however, was associated with a substantial reduction in major bleeding at 9 days and mortality at 1 and 6 months.	Enoxaparin	247-257	cAMP responsive element binding protein 3 like 1	Homo sapiens	4-9
17670627-8	2006	The mean daily substitution of platelets, red blood cells, fresh frozen plasma and anti-thrombin III-concentrate was lower in the enoxaparine group compared to both early and late unfractioned heparin-groups.	Enoxaparin	130-141	coagulation factor II, thrombin	Homo sapiens	88-96
16675258-10	2006	Heparin was given during cardiopulmonary bypass to maintain an activated clotting time above 480 s. RESULTS: Patients in the enoxaparin group needed more heparin to maintain an activated clotting time above 480 s, and had higher heparin concentrations and lower antithrombin values compared with control patients.	Enoxaparin	125-135	serpin family C member 1	Homo sapiens	262-274
16675258-11	2006	Neutrophil-activating peptide 2 concentrations were higher in the enoxaparin group.	Enoxaparin	66-76	pro-platelet basic protein	Homo sapiens	0-31
16685318-1	2006	BACKGROUND: Subcutaneous enoxaparin is increasingly employed as the antithrombin of choice in non-ST elevation myocardial infarction and in conjunction with various fibrinolytic regimens in acute ST elevation myocardial infarction (STEMI).	Enoxaparin	25-35	serpin family C member 1	Homo sapiens	68-80
16420568-0	2006	Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease.	Enoxaparin	61-71	coagulation factor II, thrombin	Homo sapiens	0-8
16420568-12	2006	Thrombin generation time appears to be more sensitive to the antithrombotic effects of enoxaparin in this population.	Enoxaparin	87-97	coagulation factor II, thrombin	Homo sapiens	0-8
16109780-6	2005	We found that anti-PF4/heparin antibodies were generated at similar frequencies in patients treated with fondaparinux or enoxaparin.	Enoxaparin	121-131	platelet factor 4	Homo sapiens	19-22
16260867-5	2005	Treatment with FGF-1 + enoxaparin resulted in a significantly increased number of capillaries compared to treatment with FGF-1 (p &lt; 0.05) and enoxaparin (p &lt; 0.05) alone.	Enoxaparin	23-33	fibroblast growth factor 1	Oryctolagus cuniculus	121-126
16260867-6	2005	Additionally, all groups treated with FGF-1 and/or enoxaparin showed a significant increase of microvessel density in the treated ischemic border zone compared to the non-treated ischemic border zone (p &lt; 0.001 for FGF-1 + enoxaparin, p &lt; 0.01 for FGF-1, p &lt; 0.05 for enoxaparin).	Enoxaparin	51-61	fibroblast growth factor 1	Oryctolagus cuniculus	218-223
16260867-5	2005	Treatment with FGF-1 + enoxaparin resulted in a significantly increased number of capillaries compared to treatment with FGF-1 (p &lt; 0.05) and enoxaparin (p &lt; 0.05) alone.	Enoxaparin	145-155	fibroblast growth factor 1	Oryctolagus cuniculus	15-20
16260867-6	2005	Additionally, all groups treated with FGF-1 and/or enoxaparin showed a significant increase of microvessel density in the treated ischemic border zone compared to the non-treated ischemic border zone (p &lt; 0.001 for FGF-1 + enoxaparin, p &lt; 0.01 for FGF-1, p &lt; 0.05 for enoxaparin).	Enoxaparin	226-236	fibroblast growth factor 1	Oryctolagus cuniculus	38-43
16260867-6	2005	Additionally, all groups treated with FGF-1 and/or enoxaparin showed a significant increase of microvessel density in the treated ischemic border zone compared to the non-treated ischemic border zone (p &lt; 0.001 for FGF-1 + enoxaparin, p &lt; 0.01 for FGF-1, p &lt; 0.05 for enoxaparin).	Enoxaparin	226-236	fibroblast growth factor 1	Oryctolagus cuniculus	38-43
16260867-7	2005	RMBF was significantly increased within the FGF-1 + enoxaparin group compared to the control group (p &lt; 0.05).	Enoxaparin	52-62	fibroblast growth factor 1	Oryctolagus cuniculus	44-49
16260867-11	2005	Thus, we conclude that enoxaparin enhances the angiogenic potential of intramyocardially injected FGF-1 in the acutely infarcted rabbit heart.	Enoxaparin	23-33	fibroblast growth factor 1	Oryctolagus cuniculus	98-103
16260867-6	2005	Additionally, all groups treated with FGF-1 and/or enoxaparin showed a significant increase of microvessel density in the treated ischemic border zone compared to the non-treated ischemic border zone (p &lt; 0.001 for FGF-1 + enoxaparin, p &lt; 0.01 for FGF-1, p &lt; 0.05 for enoxaparin).	Enoxaparin	51-61	fibroblast growth factor 1	Oryctolagus cuniculus	218-223
15957976-1	2005	Enoxaparin (Lovenox; Roule-Poulenc Rorer, Inc.), a low molecular weight heparin (LMWH), is commonly used in the management of non-ST-segment elevation acute coronary syndromes (NSTE ACS) based on clinical trial outcomes.	Enoxaparin	0-10	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	182-185
15987536-11	2005	A thromboprophylactic dose of enoxaparin inhibited PAI-1 activity but failed to down-regulate coagulation activity and D-dimer.	Enoxaparin	30-40	serpin family E member 1	Homo sapiens	51-56
15957976-1	2005	Enoxaparin (Lovenox; Roule-Poulenc Rorer, Inc.), a low molecular weight heparin (LMWH), is commonly used in the management of non-ST-segment elevation acute coronary syndromes (NSTE ACS) based on clinical trial outcomes.	Enoxaparin	12-19	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	182-185
15957976-5	2005	Antithrombin therapy with LMWH or UFH has the highest-level recommendation (IA) in the 2002 professional guidelines for the management of unstable angina and non-ST-elevation myocardial infarction, where enoxaparin has a IIA recommendation over UFH unless early coronary artery bypass surgery is planned.	Enoxaparin	204-214	serpin family C member 1	Homo sapiens	0-12
15957976-6	2005	In a recent systematic overview of &gt; 20,000 patients with NSTE ACS from six clinical trials, including conservative and invasively managed patients, enoxaparin provided a statistically significant reduction in 30-day death or nonfatal myocardial infarction (MI) compared with UFH with no significant excess in transfusions, or major bleeding.	Enoxaparin	152-162	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	66-69
15957976-7	2005	These data support the role of enoxaparin as an anti-coagulant in patients with NSTE ACS.	Enoxaparin	31-41	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	85-88
15860994-6	2005	Fibrinolytic therapy, in combination with adjunctive antithrombin therapy that is simpler and quicker to administer (e.g., tenecteplase with enoxaparin), may be more efficacious and easier to use than regimens involving unfractionated heparin.	Enoxaparin	141-151	serpin family C member 1	Homo sapiens	53-65
16124952-1	2005	BACKGROUND: In patients with non-ST-elevation acute coronary syndromes (NSTE ACS), enoxaparin has been shown to be superior to unfractionated heparin (UFH) and is associated with a reduction in ischemic end points with nonsignificant increases in bleeding.	Enoxaparin	83-93	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	77-80
16124952-3	2005	METHODS: SYNERGY was an international, multicenter, randomized, open-label trial that compared enoxaparin with UFH in high-risk NSTE ACS patients managed with an early invasive strategy.	Enoxaparin	95-105	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	133-136
16124952-11	2005	CONCLUSIONS: In patients with NSTE ACS, including high-risk patients proceeding rapidly to catheterization, enoxaparin is an effective and safe alternative to UFH.	Enoxaparin	108-118	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	35-38
16124953-9	2005	A nonsignificant trend toward higher rates of major bleeding was seen at 7 days for enoxaparin-treated patients, in both the overall safety population and the population of patients who did not receive antithrombin treatment before randomization, but there was no difference in blood transfusions.	Enoxaparin	84-94	serpin family C member 1	Homo sapiens	202-214
15815881-4	2004	Compared to control, increases in TFPI were seen with both unfractionated heparin (182% higher, p &lt; 0.001) and enoxaparin (194% higher, p &lt; 0.001).	Enoxaparin	114-124	tissue factor pathway inhibitor	Homo sapiens	34-38
15559689-7	2004	Fondaparinux is a selective, synthetic factor Xa inhibitor that has been shown to significantly reduce the risk of VTE versus enoxaparin in patients undergoing surgery for hip fracture.	Enoxaparin	126-136	coagulation factor X	Homo sapiens	39-48
16052301-0	2005	Enoxaparin in clinical practice and clinical trials of non-ST-elevation Acute Coronary Syndrome (NSTE-ACS).	Enoxaparin	0-10	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	102-105
16052301-8	2005	The effectiveness of enoxaparin compared to unfractionated heparin is now being re-considered in the era of poly-pharmacotherapy and an early invasive strategy for ACS management.	Enoxaparin	21-31	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	164-167
16052301-9	2005	We review the role of enoxaparin in the contemporary treatment of NSTE-ACS utilizing recent clinical trial data.	Enoxaparin	22-32	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	71-74
15673542-10	2005	The clinical benefits of enoxaparin as an adjunctive treatment in STEMI may be mediated in part by a reduction in vWF release.	Enoxaparin	25-35	von Willebrand factor	Homo sapiens	114-117
15467899-8	2004	Compared to baseline values 78.6% of children with total TFPI Ag &lt; 10(th) percentiles showed a low response to enoxaparin administration, whereas in children with normal baseline TFPI values 30% show a low TFPI release (p = 0.007).	Enoxaparin	114-124	tissue factor pathway inhibitor	Homo sapiens	57-61